Refractory angina pectoris. Patient characteristics, safety and long-term effects of spinal cord stimulation by Andréll, Paulin
©
Det här verket är upphovrättskyddat enligt Lagen (1960:729) om upphovsrätt till litterära och 
konstnärliga verk. Det har digitaliserats med stöd av Kap. 1, 16 § första stycket p 1, för forsk-
ningsändamål, och får inte spridas vidare till allmänheten utan upphovsrättsinehavarens
medgivande. 
Alla tryckta texter är OCR-tolkade till maskinläsbar text. Det betyder att du kan söka och kopie-
ra texten från dokumentet. Vissa äldre dokument med dåligt tryck kan vara svåra att OCR-tolka 
korrekt vilket medför att den OCR-tolkade texten kan innehålla fel och därför bör man visuellt 
jämföra med verkets bilder för att avgöra vad som är riktigt.
Th is work is protected by Swedish Copyright Law (Lagen (1960:729) om upphovsrätt till litterära 
och konstnärliga verk). It has been digitized with support of Kap. 1, 16 § första stycket p 1, for 
scientifi c purpose, and may no be dissiminated to the public without consent of the copyright 
holder.  
All printed texts have been OCR-processed and converted to machine readable text. Th is means 
that you can search and copy text from the document. Some early printed books are hard to 
OCR-process correctly and the text may contain errors, so one should always visually compare it 
with the images to determine what is correct.
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
C
M
GÖTEBORG 2005 
;JAGWAR*,: 
1001277298 
REFRACTORY ANGINA PECTORIS 
PATIENT CHARACTERISTICS 
SAFETY AND LONG-TERM E FFECTS OF 
SPINAL CORD STIMULATION 
PAULIN ANDRÉLL 
OtEßO^ 
si yyyy 
« • Si3i-
Biomedicinska biblioteket 
REFRACTORY ANGINA PECTORIS 
PATIENT CHARACTERISTICS 
SAFETY AND LONG-TERM EFFECTS OF SPINAL CORD STIMULATION 
AKADEMISK AVHANDLING 
som för avläggande av medicine doktorsexamen vid Sahlgrenska akademin 
vid Göteborgs Universitet kommer att offentligen försvaras i Centralklinikens aula, 
Sahlgrenska Universitetssjukhuset/Östra Sjukhuset, Göteborg, 
fredagen den 25 februari kl.13.00 
av 
PAULIN ANDRÉLL 
LEG LÄKARE 
Fakultetsopponent: 
Professor Lars Rydén 
Karolinska Institutet, Stockholm 
Avhandlingen baserar sig på följande delarbeten: 
I. Andréll P, Ekre O, Grip L, Albertsson P, Eliasson T, Mannheimer C. Incidence, Clinical and 
Angiographic Characteristics of Patients with Refractory Angina Pectoris — the 
Epidemiological study of Refractory Angina Pectoris (ERA). Manuscript. 
II. Andréll P, Ekre O, Grip L, Albertsson P, Währborg P, Eliasson T, Mannheimer C. Fatality, 
Morbidity and Quality of life in Patients with Refractory Angina Pectoris — A One Year 
Follow-Up of the ERA study. Manuscript. 
III. Andréll P, Jensen C, Norrseli H, Ekre O, Ekholm S, Norrsell U, Eliasson T, Mannheimer C, 
Blomstrand C. Deep White Matter Disease in Magnetic Resonance Imaging Predicts 
Neurological and Neuropsychological Complications after Coronary Artery Bypass Grafting. 
Ann Thorac Surg; 2005:79(l):74-9. 
IV. Andréll P, Ekre O, Eliasson T, Blomstrand C, Börjesson M, Nilsson M, Mannheimer C. 
Cost-Effectiveness of Spinal Cord Stimulation versus Coronary Artery Bypass Grafting in 
Patients with Severe Angina Pectoris - Long-term Results from the ESBY Study. Cardiology; 
2003;99(l):20-4. 
REFRACTORY ANGINA PECTORIS 
PATIENT CHARACTERISTICS 
SAFETY AND LONG-TERM EFFECTS OF SPINAL CORD STIMULATION 
Paulin Andréll, Multidisciplinary Pain Centre, Sahlgrenska University Hospital/Östra 
Cardiovascular Institute, Göteborg University, Göteborg, Sweden. 
ABSTRACT 
Refractory angina pectoris has been defined as severe angina pectoris due to coronary artery 
disease which cannot be controlled by conventional pharmacological or surgical therapy. The 
epidemiology of this condition is virtually unknown. 
During the last decades, additional treatment options have been developed for this condition. 
One of these is spinal cord stimulation (SCS), which has been used for approximately 20 years as an 
additional symptom-relieving treatment for patients with severe angina pectoris. SCS has an anti-ischaemic 
effect and has been shown to be a safe and effective treatment modality. 
The occurrence of refractory angina pectoris among patients who had undergone coronary 
angiography was assessed in a defined geographic area. In order to characterise the patients with regard to 
concurrent diseases, treatment, functional class, quality of life, morbidity and fatality, the refractory angina 
patients were compared with patients with severe angina pectoris who were accepted for revascularisation. 
Within three years, 146 patients were identified, comprising 2.1% of all patients undergoing coronary 
angiography due to stable angina pectoris. The patients with refractory angina pectoris had more severe 
cardiac disease as well as coronary artery disease than the patients in the revascularisation group. Some of 
the patients in the refractory group appear to be in a fairly good condition with regard to extracardiac 
diseases but there is a subpopulation in the refractory group with severe cardiac as well as extracardiac 
diseases. The main reasons for rejection for revascularisation were unsuitable coronary anatomy and a 
potential risk of damaging existing grafts. After one year of follow-up the refractory patients had a higher 
fatality rate but a lower frequency of cerebrovascular morbidity than the revascularisation group. The 
refractory patients had more severe angina and lower quality of life with regard to physical function and 
impact of angina symptoms, compared with the revascularisation group. However, the mental health of 
the refractory patients was not affected compared with the revascularisation group. 
The patients in the so-called ESBY study (Electrical Stimulation versus Coronary Bypass Surgery 
in Severe Angina Pectoris, a randomised comparison of SCS and coronary artery bypass grafting (CABG) 
in 104 patients with severe angina pectoris and increased surgical risk) were followed up with regard to 
neurological and neuropsychological complications, morbidity and cost-effectiveness. There were more 
patients in the CABG group who developed neurological and neuropsychological complications than in 
the SCS group. Furthermore, presence of deep white matter disease on cerebral magnetic resonance 
imaging was shown to be a predictor of cerebrovascular complications after CABG. During two years of 
follow-up, health care costs and cardiac morbidity was lower in the SCS group than in the CABG group. 
However, the groups did not differ with regard to mortality or causes of death. There were no serious 
complications related to the SCS treatment. 
CONCLUSION 
Refractory angina pectoris appears to be a considerable problem. This patient group has a high 
fatality rate and low quality of life compared with revascularised patients. SCS, which is one of the 
recommended treatment option for these patients, was found to be safe (in terms of mortality, morbidity 
and absence of serious complications) and effective (in terms of symptom relief and cost-effectiveness) 
during long-term treatment. Furthermore, presence of deep white matter disease on cerebral magnetic 
resonance imaging seems to be a predictor of cerebrovascular complications after CABG. 
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2. INTRODUCTION 
2.1 CORONARY ARTERY DISEASE 
Coronary artery disease (CAD) is the main manifestation of arterial atherosclerosis in the vessels 
of the heart. The close association between CAD, dietary habits, low physical activity and 
tobacco smoking has been described in recent decades.90,2'3 Diabetes mellitus, hypertension and 
hyperlipidemia are also well-known and strong risk factors for CAD.90,215 
Arterial atherosclerosis is a process that starts in the intimai tissue of the arteries. Initially lipids 
and inflammatory cells are incorporated in the vessel wall. This is followed by a continuous 
formation of fibrosis and ultimately formation of atherosclerotic plaques.114'189 As toxic and pro­
inflammatory substances are accumulated in the atherosclerotic plaque, a degeneration process 
that might make the plaque unstable starts. Hence, the atherosclerotic plaques may rupture into 
the vessel lumen, causing an acute formation of a thrombus, which, in turn, will interrupt or 
drastically impair the blood flow in the affected vessel. Furthermore, activated platelets at the site 
of the plaque rupture may release a series of vascularly active substances that will lead to 
increased vasomotor tone or even spasm. This process is clinically referred to as acute coronary 
syndrome (ACS), including acute myocardial infarction and unstable angina pectoris.54'189 In the 
chronic stage of CAD, the main problem is a relative and progressive narrowing of the arteries, 
due to atherosclerotic thickening of the vessel walls. This, in turn, impairs the arterial blood 
supply to the myocardium.16114 The chronic stage of CAD is clinically manifested as stable angina 
pectoris. 
2.2 ANGINA PECTORIS 
2.2.1 DEFINITION AND SYMPTOMATOLOGY OF ANGINA PECTORIS 
Angina pectoris is a clinical syndrome characterised by discomfort in the chest, jaw, shoulder, 
back or arm. It is typically aggravated by exertion or emotional stress and commonly relieved by 
rest.11 The syndrome was first described by William Heberden in the 18th century. Heberden 
described angina pectoris as a sense of strangling and anxiety in the chest, especially associated 
with exercise."14 The cardiac origin was not established until a few years later, when Parry 
demonstrated CAD during the necropsy of patients who had experienced the symptoms.162 The 
connection between angina pectoris and myocardial ischaemia was not established until the 20'h 
century. 118 Hence, in modem medicine the term angina pectoris is used to describe chest 
discomfort due to myocardial ischaemia associated with coronary artery disease.16 However, 
angina pectoris may also occur in persons with valvular heart disease, hypertrophic 
cardiomyopathy and uncontrolled hypertension. In addition, the symptoms may be present in 
patients with normal coronary arteries and myocardial ischaemia related to spasm or endothelial 
dysfunction. Angina-like chest pain may also be the main symptom in patients with non-cardiac 
conditions such as oesophageal, chest wall or lungsdisorders.16,91 
Stable angina pectoris is defined as anginal symptoms occurring over several weeks without any 
major deterioration.16 Even in stable angina the symptoms may vary considerably, depending on 
factors such as weather or emotional stress. 
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Unstable angina pectoris has been described by Braunwald and is divided into three classes; a) debut 
of anginal symptoms that markedly limit physical activities, b) abrupt worsening of pre-existing 
stable angina, for example, more anginal episodes and longer duration of the anginal attacks, and 
c) anginal symptoms occuring at rest.38 However, some patients may present a mixed 
symptomatology. For this reason, sometimes it may be difficult to distinguish clinically between 
these conditions. Furthermore, pathologically the patients may have features of both stable and 
unstable angina.16 
Prinzmetal angina is a rare c ondition that develops spontaneously with ST elevation on the 
electrocardiogram (ECG). It is believed that the pain and the ECG changes are due to an increase 
in coronary tone or epicardial spasm, often in combination with ventricular arrhythmias and 
atrioventricular block/9'68,119 Prinzmetal angina is also referred to as vasospastic angina.16 
Cardiac syndrome X is described as a syndrome in which angina pectoris occurs in the absence of 
apparent coronary atherosclerosis or other organic disease of the epicardial arteries according to 
angiographic findings, but where presents objective evidence of myocardial ischaemia in terms of 
ST segment depression on ECG during stress."' Recent studies indicate that the anginal 
symptoms occur due to endothelial dysfunction , sometimes referred to as "microvascular 
angina" in the literature.57'79,160 However, patients with chest pain and normal coronary arteries 
have a good prognosis in contrast to patients with angina pectoris and CAD.3 11 
The severity of anginal symptoms are commonly graded according the Canadian Cardiovascular 
Society's (CCS) classification (table l).45 
TABLE 1. Classification of angina pectoris according to the Candian Cardiovascular Society. 
Class I "Ordinär)' physical activity does not cause angina" — such as walking or climbing stairs. Angina with 
strenuous or rapid or prolonged exertion at work or recreation. 
Class II "Slight limitation of ordinary activity" - walking or climbing stairs rapidly, walking uphill, walking or 
climbing stairs after meals, in cold, or in wind, or when under emotional stress, or only during the 
few hours after awakening. Walking more than two blocks on the level and climbing more than one 
flight of stairs at normal pace and in normal conditions. 
Class III "Marked limitations of ordinary physical activity" - walking one or two blocks on the level and 
climbing one flight of stairs in normal conditions and at normal pace. 
Class VI "Inability to carry on any physical activity without discomfort" - anginal syndrome may be present 
at rest. 
2.2.2 PREVALENCE OF ANGINA PECTORIS 
The prevalence of angina pectoris increases with age, from 2-5% in men in the age group 45-54 
years, to 11-20% in the age group, 65-74 years. Angina pectoris is less common in women in the 
same age groups: 0.5-1% and 10-14%, respectively.16 The prevalence of angina pectoris in 
Sweden is estimated to be approximately 1-4.5% in men 40-55 year old and about 6% in 60-year 
old men.164 In total, one per cent of the Swedish population is estimated to suffer from angina 
pectoris and the incidence of angina pectoris is approximately 16 000 new cases per year in 
Sweden.1 
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2.2.3 PATHOPHYSIOLOGY OF ANGINA PECTORIS 
The heart is an aerobic organ, not designed for anaerobic work. The heart is dependent on 
almost complete oxidation of nutrients to obtain energy. At rest, the oxygen extraction fraction 
from the myocardial blood is approximately 75%, which is high compared with other kinds of 
tissue. Thus, the possible increase in oxygen extraction is quite limited.20' Due to the inability of 
the myocardium to function without proper oxygen supply, balance between the supply and 
demand of oxygen is critical. Imbalance, and subsequent myocardial ischaemia, may be caused by 
poor myocardial perfusion (blood and oxygen supply), inreased oxygen demand or both. The 
cause may vary in the same patient on different occasions. 
In healthy subjects cardiac stress will induce dilatation of the coronary arteries as a result of 
increased myocardial oxygen demand. As the myocardial blood flow increases to meet the 
increased demand, the balance between myocardial perfusion and oxygen demand is maintained. 
At rest and during myocardial stress, the myocardial perfusion will always be sufficient for 
maintaining an aerobic metabolism. In contrast, in persons with angina pectoris, usually during 
exercise with subsequent increased oxygen demand, the coronary arteries are not able to dilate 
sufficiently, due to thickening and stiffness in the vessel walls caused by atherosclerosis. The 
myocardial oxygen demand will be greater than the myocardial perfusion, an aerobic metabolism 
cannot be maintained and ischaemia occurs in the myocardium. Ischaemia is characterised by 
insufficient coronary blood flow, insufficient supply of oxygen and nutrients and insufficient 
removal of metabolic rest products.35 
During ischaemia, glycolysis is accelerated and the glycogen is rapidly consumed in the 
myocardial tissue. The aerobic metabolism switches to anaerobic metabolism, resulting in 
decreased formation of ATP and accumulation of metabolites, especially lactate that reduces the 
pH in the myocardial tissue. The ischaemic pain probably arises from an increase in algogenic 
substances, such as lactate, protons, potassium, bradykinin and adenosine, which stimulate the 
pain-transmitting neurons.2"4 The pain perception of the heart is believed to be transmitted 
mainly via chemoreceptors.56 
2.2.4 CARDIAC PAIN 
Pain occurs late in the progression of myocardial ischaemia.141'204 The first result of myocardial 
ischaemia is impaired myocardial performance due to initial diastolic and then systolic 
dysfunction, leading to elevated left ventricular filling pressure. This is followed by electrographic 
changes and, finally, anginal pain may develop.141 
Ischaemia is the pathophysiological stimulus of cardiac pain. When ischaemia develops, algogenic 
substances are formed which activate chemoreceptors in sensory nerve endings in the adventitia 
of the coronary arteries, in the subepicardial tissue and in the myocardium. The cardiac pain 
afferents mainly consist of small myelinated A delta fibres and unmyelinated C fibres.47'2"4 These 
primary afferents from the three major cardiac nerves run together with the sympathetic and 
parasympathetic nerves to reach the cervical and stellate ganglia. Afferent nerves from the 
thoracic ganglia enter the dorsal column of the thoracic spinal cord via the thoracic dorsal spine 
roots. Just before entering the spinal cord, the heart's innervation spreads upwards and 
downwards over several segments, but the majority of the axons terminate in the Thl-Th5 
segments of the spinal cord."04 In the spinal cord the pain signal is transmitted via the spino­
thalamic tract to the brain. In the brain the pain signal is processed in the thalamic nuclei and 
projected to the somato-sensory cortex, the pain signal is processed and the location of the pain 
is identified. Activity can be observed in the hypothalamus, the reticular formation and the 
amygdala in response to arousal, fear and autonomic activation. Cognitive appraisal of the pain 
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signal occurs in the parietal cortex and the anterior cingualte cortex, the situation will be assessed 
as intrusive and threatening, an unpleasant experience. This causes activation of the pre-frontal 
cortex and the limbic system, the pain signal is processed emotionally, resulting in apprehension 
and fear for the future, the pain signal is evaluated in terms of the threat it represents to well-
being or life.135 
2.2.4.1 Asymptomatic myocardial ischaemia 
In many cases myocardial ischaemia is not accompanied by anginal pain. This condition is 
referred to as silent myocardial ischaemia. Up to 70% of the episodes of myocardial ischaemia in 
patients with CAD may be asymptomatic; for acute myocardial infarction, the incidence of 
painless events is estimated to be approximately 25%.6fl'115,186 In addition, there is a group of 
patients who do not experience any anginal symptoms at all during myocardial ischaemia. The 
phenomenon has not yet been fully explained. It has been suggested that silent myocardial 
ischaemia might occur due to inconsistent processing of the pain signals in the central nervous 
system.180 Studies of regional cerebral blood flow during myocardial ischaemia have suggested 
that cortical activation is necessary for the sensation of pain, while subcortical structures, for 
example the thalamic nuclei, may be affected during silent ischaemia as well as during painful 
ischaemia. 1,81811 Furthermore, the distribution of cerebral blood flow during myocardial 
ischaemia seems to differ in patients with cardiac syndrome X from that in patients with CAD.181 
Results from a previous study indicate that the central neural handling of afferent signals may be 
altered in patients suffering from cardiac syndrome X, which may contribute to an abnormal pain 
perception in these patients.181 
2.2.4.2 Referred pain 
Pain from the heart, as well as from other visceral organs, is experienced as referred pain. The 
area of localisation corresponds to the dermatomes supplied by the thoracic spinal roots. There 
are several explanations for the phenomenon of referred pain. The most accepted hypothesis is 
"the convergence theory".151 The convergence theory states that there are a great number of 
viscero-somatic convergences in the dorsal column. The brain is unable to determine the original 
visceral source of the pain and instead localises the pain to the corresponding somatic structure. 
Another theory explaining the referred phenomenon is "the occurrence of dichotomising 
afferents," i.e. one nerve supplies two or more axons to a visceral and somatic structure 
simultaneously.47,193 Furthermore, another theory, proposed by MacKenzie, suggests that 
"irritable foci" are created in the dorsal column, making the neurons increasingly sensitised to 
normally physiologically non-painful stimuli from somatic structures, resulting in the brain 
localising the pain to those somatic structures instead of to the visceral organs.153 
2.2.4.3 Differential diagnosis of chest pain 
There are many diseases that may give rise to chest pain resembling angina pectoris.34,39 Due to 
the referred pain phenomenon, anginal pain may be difficult to distinguish from pain from other 
visceral organs in the thorax. 
Conditions in the oesophagus (gas tro-oesophageal reflux, oesophageal dysmotility) may be especially 
difficult to differentiate from anginal pain, as disturbances in the organs may occur 
simultaneously and they are closely related anatomically. Furthermore, dysfunction in one of the 
organs may influence the other organ, either directly by reflex mechanisms, i.e. linked angina (a 
viscero-visceral reflex), or indirectly by modifying the afferent flow from the other organ.33,49,204 
13 
Other diseases of the heart, aorta and lungs, for example aortic stenosis, aortic dissection, thoracic 
aortic aneurysm, severe pulmonary hypertension and perimyocarditis, may give rise to chest pain, 
which may be difficult to differentiate form angina pectoris in the acute phase. 
Pain from the chest wall.\ suc h as musculoskeletal pain, Tietze's syndrome and thoracic back pain 
with secondary neuralgia, may be difficult to distinguish from anginal pain. Post-CABG pain may 
be even more difficult to differentiate from angina pectoris. The former condition is primarly 
seen in patients who have undergone coronary artery bypass grafting (CABG) using the internal 
mammary artery. It is believed that this condition is due to damage to the intercostal nerves when 
the internal mammary artery is dissected, causing intercostal neuralgia that is associated with 
hypoesthaesia and mechanic allodynia (pain due to a stimulus that does not normally provoke 
pain).53'70 
Visceralpain from the abdomen, e.g. peptic ulcer, gastritis, pancreatitis and gall bladder disease may 
also give rise to chest pain. 
Functionalpain, where there is no evidence of somatic pathology; for instance, anxiety disorders, 
often combined with depression, is another differential diagnosis in anginal pain. 
2.2.5 DIAGNOSIS OF STABLE ANGINA PECTORIS 
In patients with chest pain that is considered to be of cardiac origin there is a need to assess 
whether the chest pain is due to myocardial ischaemia and CAD. The anginal pain is often 
characteristic, presenting four cardinal features; location (usually retrosternal with radiation to the 
chest and the arms), relationship with exercise (the symptoms are provoked by exercise), 
character (discomfort/feeling of pressure/strangling sensation), and duration (symptoms are 
relieved after rest within 1-3 minutes). Furthermore, patients with stable angina pectoris respond 
promptly, usually within 30 seconds, to sublingual nitrates. Hence, a clinical assessment and the 
patient's history often suffice to establish the diagnosis of stable angina pectoris. i6'91 After clinical 
assessment, non-invasive investigations, such as ECG stress testing, myocardial perfusion 
scintigraphy and stress echocardiography, are usually performed in order to confirm myocardial 
ischaemia, to assess the prognosis and to select the most appropriate therapies. However, non­
invasive investigations are not always conclusive, or the patient may not be able to participate in 
the investigations properly so as to allow for conclusive results to be achieved. Thus, stable 
angina pectoris is ultimately a clinical diagnosis. In contrast, CAD is an angiographic diagnosis. 
CAD is often, but not always, associated with myocardial ischaemia and angina pectoris. 
2.2.6 NON-INVASIVE INVESTIGATIONS 
ECG exercise test (bicycle ergometer or treadmill tests) is the first choice of investigation after 
clinical assessment in most patients. ECG stress testing is a generally a safe procedure: it is a 
simple test and the least expensive investigation for confirming ischaemia. ECG changes during 
exercise are associated with the presence of CAD with a sensitivity of 50-80% and a specificity of 
80-95%.16'91 The greatest sensitivity can be found in patients with multi-vessel disease. Exercise 
testing is less sensitive in women than in men, and some studies have indicated that it is also less 
specific.16'" In addition, ECG changes in the absence of CAD are seen in patients with 
conditions such as cardiac syndrome X. A disadvantage with exercise tests is that they are 
dependent on the patient's ability to participate in the investigation for a conclusive result of the 
test to be obtained. For instance, conclusive results can usually not be obtained in patients with 
claudication, arthrosis of the knees/hips or obstructive pulmonary disease, as their exercise 
capacity is limited due to other reasons than myocardial ischaemia. Pharmacological stress tests, 
which do not require patient compliance, are more suitable in these patients. 
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Myocardialperfusion scintigraphy is often performed in association with a symptom-limited exercise 
test on a bicycle but can also be performed in association with pharmacological stress testing. 
The sensitivity (65-90%) and specificity (90-95%) is somewhat higher than those of exercise ECG 
test.16'91 The test is used in patients who are unable to take part in exercise testing, or as an 
additional test when the results of the ECG stress test are inconclusive. Myocardial perfusion 
scintigraphy is also recommended for patients who have previously been revascularised. 
Myocardial perfusion scintigraphy allows more precise localisation of the vascular territories 
involved, particularly identification of single-vessel disease. 
Stress echocardiography, like myocard ial perfusion scintigraphy, is an alternative to classical exercise 
testing with ECG. The test is suitable for the same patient groups as those for whom myocardial 
perfusion scinitgraphy is the test of choice. Stress echocardiography has the same sensitivity (65-
90%) and specificity (90-95%) as myocardial perfusion scintigraphy and is less expensive.161,1 The 
method has a high sensitivity of detection of single-vessel and multi-vessel disease. However, 
proper interpretation of the test requires considerable experience and expertise. 
2.2.7 INVASIVE INVESTIGATIONS 
In order to assess whether clinically important obstructive coronary atherosclerosis is the cause 
of the patient's anginal symptoms and in order to determine whether the CAD is available for 
treatment with revascularisation procedures such as percutaneous coronary intervention (PCI) or 
CABG, a coronary angiography is usually performed. During the coronary angiography 
narrowing of the vessels caused by atherosclerosis is assessed visually. A stenosis in the epicardial 
vessels is usually considered clinically significant, i.e. the coronary blood flow is inadequate to 
meet the metabolic demands of the heart during exercise or stress, if the vessel lumen is 
narrowed by at least 50% of the lumen diameter.16 However, the clinical importance of the 
stenosis is also dependent on the length and relative percent narrowing of the stenosis as well as 
the number of stenoses. Furthermore, the luminal diameter of the stenoses is not fixed and may 
alter with changes in coronary tone due to local smooth muscle constriction or dilatation. 
Visual interpretation of coronary angiography is known to carry a h igh interobserver variability."1 
Furthermore most interventionists tend to overestimate the degree of stenosis prior to an 
intervention such as PCI and underestimate the residual narrowing after the treatment..2' To 
handle these problems quantitative coronary angiography (QCA) has been developed."'8 With this 
method, using automatic contour detection with minimal manipulation by the operator, stenoses 
can be measured with high accuracy and low intraobserver as well as interobserver variability. 
Even though coronary angiography is the cornerstone for assessment of epicardial coronary 
lesions, the method is limited since complex plaque morphology is difficult to assess and since 
the method does not provide any physiological information.2"8 Hence, Gould et al. 
developed coronary flow reserve (CRF) as a method for assessing the haemodynamic 
consequences of coronary stenoses. During the 1990s, the CRF has developed into fractional 
flow reserve (FFR), which has emerged as an important physiologic adjunct to coronary 
angiography for the assessment of intermediate lesions.30 Haemodynamic studies have indicated 
that the resting coronary flow is not altered until a constriction of at least 85% by diameter is 
present but the maximal coronary flow is affected by a constriction as small as 30%.93 
Even if a stenosis is considered clinically significant according to coronary angiography and 
haemodynamic measurements, the stenosis significance to the patient is dependent on collateral 
flow. A plaque rupture with a sudden formation of a stenosis, even if moderate, might cause 
severe symptoms if there is no collateral flow. On the other hand, a severe stenosis, or even an 
occlusion, which have been formed successively might be well tolerated as a collateral flow in 
most cases already has been established. 
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Despite the shortcomings of visual assessment of coronary angiographies this method is, to date, 
the most feasible to assess the overall distribution and severity of CAD. 
2.3 CONVENTIONAL TREATMENT OF STABLE ANGINA PECTORIS 
The aim of treatment is to minimise or to abolish angina symptoms and to prevent further 
progress of the CAD. The two main determinants for myocardial ischaemia are myocardial 
perfusion and myocardial oxygen consumption. Thus, these factors are the main targets for the 
therapeutic approach in the treatment of angina pectoris. 
Before, or in connection with initiation of pharmacological therapy, lifestyle changes, in terms of 
smoking cessation, dietary changes, weight reduction and increased physical activity, should be 
applied. Furthermore, concomitant diseases such as hypertension, dyslipidaemia and diabetes (as 
the diseases affect the progression of CAD), should be appropriately treated. 
2.3.1 PHARMACOLOGICAL TREATMENT 
Pharmacological treatment of angina pectoris encompasses both the prevention of complications 
of CAD and symptom relief. Conventional symptom-relieving pharmacological treatment in 
angina pectoris consists of nitrates, beta-blockers and calcium antagonists. 
Nitrates are one of the cornerstones in the symptomatic treatment of angina pectoris. Short-acting 
nitrates work rapidly and usually relieve the anginal pain within minutes. Long-acting nitrates are 
used for prophylactic treatment of angina pectoris. Nitrates decrease myocardial oxygen 
consumption by causing vasodilatation, predominantly venodilatation, which leads to a decrease 
in ventricular pre-load. In addition, nitrates produce less pronounced systemic arterial dilatation 
(resulting in a decrease in afterload) and coronary artery dilatation (increasing myocardial 
perfusion). A disadvantage is the rapid development of tolerance to the substance.16'91 The 
development of tolerance can be overcome by the use of nitrate-free intervals between dosing. 
Beta-blockers act mainly by blocking the beta,-receptor. "Non-selective" beta-blockers also block 
the beta2-receptor but even "selective" beta-blockers also have an effect upon this receptor. Beta-
blockers slow down the heart rate, reduce myocardial contractility and decrease arterial 
pressure."''91 These effects reduce the myocardial oxygen demand. Beta-blockers have been 
shown to improve survival in patients with previous myocardial infarction.9'159 In addition, beta-
blockers are used in the treatment of hypertension, arrhythmias, cardiomyopathy and congestive 
Caldum antagonists act by blocking calcium channels, causing a decrease in intracellular calcium 
levels which produces arterial smooth muscle relaxation and decreases the systemic blood 
pressure through coronary and peripheral vasodilatation. The reduced intracellular calcium levels 
cause a reduction in myocardial contractility, which, in turn, reduces oxygen consumption. It has 
also been shown that calcium antagonists increase coronary blood flow.16'98 However, the clinical 
significance of this finding has been debated. The calcium antagonists are a heterogeneous group 
with important differences in terms of pharmacological action. The three main classes are 
phenylalkylamines, benzothiazepines and dihydropyridines. In stable angina pectoris, long-acting 
dihydropyridines (e.g. felodipine, amlodipine) seem to be useful, as they are more vascular-
selective and have less negative inotropic effects.98 However, the present consensus is that short-
acting dihydropyridines should no longer be used in the treatment of CAD.98 Calcium antagonists 
are generally as effective as beta-blockers at relieving angina.91 However, the efficacy of adding a 
calcium antagonist to patients already medicated with beta-blockers has been discussed during 
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the last few decades. There are studies, however, supporting the theory that addition of calcium 
antagonists to beta-blockers may be of value.88,123,166 
Platelet inhibitors, such as aspirin and Clopidogrel, are anti-thrombotic and are used in angina 
pectoris in order to prevent complications of CAD. Aspirin may also be active through anti­
inflammatory effects on the atherosclerotic process. Clopidogrel is used as an alternative for 
patients who are allergic or intolerant to aspirin. Platelet inhibitors have been shown to reduce 
vascular events in patients with stable angina pectoris and to improve survival in the ACS.1"'1'" 
Benefits of the combination of aspirin and Clopidogrel have been demonstrated in patients with 
ACS and patients undergoing percutaneous coronary intervention (PCI).143,219 Furthermore, 
platelet inhibitors seem to have beneficial effects on the occlusion rate of vein grafts after 
CABG.9' 
IJpid-lowering agents, such as statins, have been shown to reduce the risk of myocardial infarction, 
death and the need of coronary bypass surgery in patients with stable angina pectoris and 
elevated total cholesterol level.13 Furthermore, there are reports indicating anti-ischaemic effects 
of statins at least in the acute phase of CAD. The mechanisms that have been suggested are 
plaque stabilisation, anti-inflammatory effects, anti-thrombotic effects and improved endothelial 
function. These mechanisms may be independent of lipid levels, suggesting that all patients with 
CAD might benefit from statin therapy, regardless of cholesterol levels.23'69,198'211 
ACE inhibitors have been shown to reduce the incidence of cardiovascular death, myocardial 
infarction and stroke in high-risk patients with diabetes or vascular disease and one 
cardiovascular risk factor, even in the absence of heart failure.218 Furthermore, results from 
previous studies indicate that ACE inhibitors may increase coronary blood flow.122 However, the 
clinical importance of this effect has not yet been demonstrated. Treatment with ACE inhibitors 
is indicated in patients with CAD who also have diabetes and/or left ventricular systolic 
dysfunction according to the American guidelines for management of patients with chronic stable 
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angina. 
2.3.2 INVASIVE TREATMENT 
When pharmacological therapy fails to reduce the anginal symptoms, invasive treatments - i.e. 
revascularisation procedures, such as CABG or PCI - may offer further symptom relief. In 
addition, CABG is indicated in patients with impaired left ventricular ejection fraction (LVEF), 
three-vessel disease and/or left main stenosis irrespective of the patient's symptoms, as several 
studies have shown favourable effects on survival in this patient group after surgery.(''11,78,113,220 
CABG has been used in the treatment of angina pectoris for more than 30 years. The treatment 
modality is considered beneficial, including a survival benefit in patients with left main stenosis or 
proximal three-vessel disease or two-vessel disease including proximal stenosis of the left anterior 
descending (LAD) artery.113,22" CABG efficiently improves the symptoms in patients with angina 
pectoris: freedom from angina up to five years after surgery in 80% of the patients has been 
described.11,83 A disadvantage of CABG is that it involves major surgery, which in especially in 
patients with more progressive CAD and/or extracardiac disease results in a risk o f adverse 
outcome.1""'1"6,2"" Hence, CABG is a treatment modality associated with a non-negligble risk of 
complications in connection with the procedure. The in-hospital mortality rate is about 1 to 5% 
of the cases, depending on the preoperative extent of CAD and on preoperative LVEF.16 The 
mortality rate in connection with repeat revascularisation in patients who have previously 
undergone CABG is high. After prior CABG, the one year mortality rate after consecutive PCI is 
approximately 11-12 percent, compared with 5-21 percent after repeat CABG.16 '31 
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Perioperative myocardial infarction may be observed in approximately 5% of the patients and 
major neurological complications in patients undergoing CABG occur in about 2% of the 
patients, although there have been reports of complication rates ranging from 1% to 5%.16'42-143'173 
Furthermore, the percentage of patients suffering from neuropsychological dysfunctions is high 
at hospital discharge, approximately 50 to 90 percent.'35,19(1 During the first decades, the CABG 
procedure was performed using extracorporeal circulation with a pump oxygenator and 
cardioplegia. However, the outcome after CABG seems to have improved due to the 
development of surgical and anaesthesiological management.16,91 A problem with CABG is low 
patency rate of the vein grafts. Within one week of surgery 10-20% of the grafts are occluded 
from thrombosis and by three to five years after the operation, 60-70% of the vein grafts show 
evidence of atherosclerotic narrowing and after ten years, 50% are occluded.16,91'97 In contrast, 
90% of the internal mammary artery grafts anastomosted to the LAD are patent ten years after 
surgery.132 
PCI is a less invasive procedure that was introduced in the treatment of angina pectoris in the late 
1970s. In this strateg}' a catheter-borne balloon, introduced percutaneously via the femoral or 
radial artery, is inflated at the point of the coronary stenosis, dilating the stenosis. The number of 
procedures has increased dramatically and PCI has surpassed the frequency of CABG as it is a 
less costly treatment modality than CABG and the patients can return to activity earlier. PCI is 
considered suitable for patients with single-vessel or two-vessel disease, which does not involve 
the left main stem or the proximal LAD. Compared with medical treatment, studies have 
indicated that PCI is more efficient at relieving symptoms of angina pectoris.161 Jones et al. 
demonstrated improved survival of PCI versus medical treatment in patients with single-vessel 
disease without LAD stenosis, but there is no evidence of a reduced risk of myocardial infarction 
by PCI treatment compared with medical treatment.113,161 
The mortality rate in connection with the procedure is 0.2% in patients with single-vessel disease 
and 0.5% in patients with multi-vessel disease.16 However, there is a risk of acute coronary 
occlusion during PCI. This risk has been reduced due to the advent of stents and improved 
antithrombotic therapies. To date, perioperative myocardial infarctions occur in less than 1% of 
the cases. A major disadvantage of PCI treatment is the high frequency of restenosis, which 
occurs in 30-40% of cases treated with ballon angioplasty.16,91 
The general usage of stents and platelet inhibitors have decreased the frequency of restenosis 
compared with ballon angioplasty solely.19,126,145 Furthermore, the recent development of drug 
eluting stents, with capability to release antiproliferative drugs to the vessel wall, carry the 
possibility of reducing the restenosis problem to only a few percent. The risk complications in 
connection to reintervention is low and repeat PCI, with our without stent implantation, can be 
performed with a high success rate.16 
CABG and PCI are both effective at reducing anginal symptoms by re-establishing the blood and 
oxygen supply to the affected myocardium. In randomised studies, early and late survival rates as 
well as the frequency of myocardial infarction have been equivalent for PCI and 
CABG.14,13'95,1113,121 P atients undergoing CABG present fewer angina symptoms and require fewer 
anti-anginal drugs than patients undergoing PCI. 
The CABG involves longer hospitalisation and convalescence thereafter, but PCI requires more 
reinterventions. Thus, the choice of approach, besides coronary anatomy factors, rests on 
weighing the more invasive nature of CABG against the greater risk of recurrent angina and 
reintervention over many years after PCI. 
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2.4 REFRACTORY ANGINA PECTORIS 
2.4.1 DEFINITION AND DIAGNOSIS 
Despite conventional pharmacological and invasive therapy, there is a group of patients who 
suffers from chronic severe disabling angina pectoris. This condition has been described with 
different terms such as intractable angina pectoris, end-stage CAD and refractory angina 
pectoris.12n'133'188 The terms end-stage CAD and intractable angina pectoris are less suitable, as 
they imply a condition that is inaccessible to any further treatment. The refractory patients do 
suffer from end-stage CAD, as further revascularisation procedures are not feasible due to their 
coronary anatomy. However, refractor}7 angina pectoris is a more appropriate term, as it indicates 
that the condition is refractory or resistant to conventional treatment modalities, but may be 
available for other treatment options.133 Hence, the refractory patients' angina pectoris disease 
should not be considered an end-stage disease. 
According to a report by the European Society of Cardiology (ESC) joint study group on the 
treatment of refractory angina pectoris, which is based on the European Heart Journal's 
guidelines for management of stable angina pectoris and the American guidelines for the 
management of patients with chronic stable angina, refractory angina pectoris is defined as 
follows: 
Refractory angina pectoris is a chronic condition characterised by the presence of a ngina caused by coronay 
insuffiâency in the presence of coronary artery disease which cannot be controlled by a combination of medical 
therapy, angioplasty and coronary bypass surgery. The presence of reversible myocardial ischaemia should be 
clinically established to be the cause of t he symptoms. Chronic is defined as a duration of more t han 3 months. 
In order to be considered refractory the patient has to have optimum medication. The word 
"optimum" is used rather than "maximum" as a considerable number of patients do not tolerate 
triple combination therapy (nitrates, beta-blockers, calcium antagonists) due to side effects: for 
example, hypotension, bradycardia and subjective discomfort.""7 Furthermore, conventional 
revascularisation procedures (PCI or CABG) must be ruled out on the basis of a recent coronary 
angiogram and the presence of CAD must be established. In addition, the presence of myocardial 
ischaemia should be established before alternative treatment modalities are considered. However, 
as most patients with refractory angina pectoris have global and diffuse coronary insufficiency 
and a low exercise capacity, detection of myocardial ischaemia may be difficult to achieve with 
conventional investigations (ECG exercise testing, myocardial perfusion scintigraphy).188 It has 
been suggested that stress echocardiography might be a more suitable investigation method in 
this patient group as it includes regional wall motion analysis of the ischaemic myocardium.188 
However, stress echocardiography is not always available and the result and conclusiveness of the 
investigation is dependent on the performer. Hence, the report by the joint study group's on the 
treatment of refractory angina pectoris underlines that myocardial ischaemia as a cause of angina 
pectoris is ultimately a clinical diagnosis.113 According to the report, the patients suffering from 
refractory angina pectoris must have severe angina pectoris. The majority of patients with mild to 
moderate angina (CCS class 1-2) can be adequately treated with conventional anti-anginal 
medication.120 Furthermore, due to the potential risk of complications in connection with 
revascularisation procedures, invasive treatment is usually not considered as an option for 
symptomatic treatment only, in patients with mild to moderate angina. Hence, only patients with 
severe angina (CCS class 3-4) are considered refractory when rejected for revascularisation as 
invasive treatment is indicated for symptom relief in theses patients. 
Secondary prevention of CAD, including improved drug therapy (aspirin, beta-blockers and lipid-
lowering agents) and the development of revascularisation techniques seem to have reduced 
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mortality among patients with CAD in the last decades.188'213 It has been suggested that the 
number of patients with refractory angina pectoris increases, partly due to this improvement in 
survival.135'188 According to Yang et al. the number of patients suffering from refractory angina 
pectoris is estimated at 300 000 to 900 000 patients in the United States and 25 000 to 75 000 
new cases are diagnosed each year.216 In a Swedish survey of patients referred for coronary 
angiography due to stable angina pectoris, performed by the Swedish Council of Technology 
Assessment in Health Care in 1994-1995, it was shown that 9.6% of the patients referred for 
angiography were rejected for revascularisation despite severe angina.40 
Until recently, this patient group seems to have been more or less ignored, probably because they 
are not available for conventional treatment. The responsible physician often informs the patient 
that "nothing more can be done", which is very depressing for the patient. However, additional 
symptomatic treatment modalities for refractory angina pectoris have been developed during the 
last few decades. The epidemiology of refractory angina pectoris is virtually unknown and the 
patient group has not been described in terms of co-morbidity, nor have the reasons for rejection 
for revascularisation been systematically characterised. In order to form a basis for specific 
guidelines concerning the management and treatment of patients with refractory angina pectoris, 
there is a need for further studies of this patient group. 
2.4.2 ADDITIONAL SYMPTOMATIC TREATMENT MODALITIES FOR STABLE ANGINA 
Several therapeutic approaches have been developed for symptom control in refractory angina 
pectoris during the last decades and numerous reviews have been published on the treatment of 
refractory angina pectoris.63'120'135'188,203'216 In the field of pharmacological treatment, therapy with 
opioids, intrathecally applied anaesthetics and opioids, additional antiplatelet agents, low-
molecular-weight heparins, thrombolytic agents and partial fatty acid oxidation inhibitors (e.g. 
ranolazine and perhexiline), are being discussed as additional pharmacological therapy options in 
patients with refractory angina pectoris.63'120-188'216 However, the documentation regarding the 
efficacy and safety of these treatments in refractory angina pectoris is so far limited. Furthermore, 
some of the pharmacological treatments have major drawbacks as long-term therapies; for 
example, opioids, because of the risk of development of dependence and the gastro-intestinal 
side effects of the treatment, and intrathecal treatment because of the risk of intraspinal infection. 
In addition, there are several non-invasive non-pharmacological and invasive treatment 
modalities available for the treatment of refractory angina pectoris. In Europe, neuromodulation 
techniques (i.e. transcutaneous electrical nerve stimulation (TENS) and spinal cord stimulation 
(SCS)), enchanced external counterpulsation (EECP), thoracic epidural anaesthesia (TEDA), 
endoscopic thoracic sympathicotomy (ETS), stellate ganglion blockade (SGB) and laser 
revascularisation, i.e. transmyocardial revascularisation (TMR) and percutaneous myocardial 
revascularisation (PMR) are being used.27-5l'84'95'l35'l37-l54-17,'20<i'214 
The main effect of neuromodulation is decreasing myocardial oxygen consumption. It has been 
suggested that the main effect of TEDA, ETS and SGB is modulation of sympathetic activity. 
Laser revascularisation and EECP aim at increasing myocardial perfusion, but the documentation 
to date regarding long-term effect of these treatments on myocardial perfusion is limited. 
Another evolving therapeutic concept is vascular endothelial growth factor (VEGF).131,205  
Furthermore, cardiac rehabilitation programmes, including stress management and regular 
physical exercise might be of value in this patient group.63'135 
In the report by the ESC joint study group on the treatment of refractory angina pectoris, 
neuromodulation (TENS and SCS) is recommended as the first choice of treatment in refractory 
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angina pectoris, as neuromodulation seems to be the treatment with the best documentation 
concerning the efficacy and safety in angina pectoris.135 
2.5 BACKGROUND OF NEUROMODULATION 
The neuromodulation techniques have evolved from Melzack and Wall's "gate control theory". 
This theory was proposed in 1965 to explain the modulation of afferent pain signals in the spinal 
cord. According to the gate control theory activation of large afferent, non-nociceptive 
myelinated type A fibres (transmitters of mechanic stimuli) inhibit the transmission of 
nociceptive impulses through smaller unmyelinated type C fibres in the relaying areas of the 
dorsal horn of the spinal cord, thereby "closing the 
gate" for the nociceptive impulses.146 On the basis of 
this theory, dorsal column stimulation, later called 
spinal cord stimulation (SCS) was developed (Fig.l). 
The technique was introduced in humans in the late 
1960s, when low voltage current was applied to the 
dorsal part of the spinal cord, thereby mimicking the 
effect of activation of the type A fibres.1"" 
Transcutaneous electrical nerve stimulation (TENS) 
was introduced during this time, but it was only meant 
to be used for selection of patients for subsequent SCS 
treatment.14" However, to date TENS is used for 
treatment in variety of pain conditions. 
SCS is used in the treatment of a number of different 
pain conditions. The four main indications are 
neuropathic pain, so called failed back surgery 
syndrome (FBSS), peripheral vascular disease, and 
angina pectoris. The characteristics of the pain-
relieving effect of SCS are different in these conditions, 
implying that SCS may have different mechanisms of 
action. Thus, in peripheral neuropathic pain the 
symptoms decline after 10-20 minutes and this effect is 
subtotal. In contrast, in ischaemic pain conditions, 
such as angina pectoris, the pain-relieving effect occurs 
within 30-60 seconds and is usually complete. This difference can be used clinically to 
differentiate between ischaemic pain and pain from of non-ischaemic origin. 
Approximately 50-60% of the patients treated with SCS for neuropathic pain experience adequate 
pain relief.43'74 Studies have indicated that the main mechanism of pain relief in neuropathic pain 
is SCS-induced modulation of the neural activity in the spinal cord, involving changes in local 
transmitter systems.128 It has also been suggested that activation of supraspinal loops may be of 
importance.128 
In the 1970s, SCS was introduced by Cook et al. as treatment of pain due to peripheral vascular 
disease.55 SCS was found to relieve pain in patients with nonreconstructable peripheral vascular 
disease, resulting in improved mobilisation which enhanced the blood flow, leading to ulcer 
healing and reduced need to amputate.25'1"8 I t has been suggested that the underlying mechanism 
of pain relief by SCS in peripheral vascular disease is the improvement in the microvascular blood 
flow and a decrease in sympathetic tone.111'1" In patients treated with SCS for peripheral 
vascular disease, about 60-70% of the patients experience pain relief.41'74'"1 
E Aj 
FIGURE 1. Ail iamplanted SCS system. 
E= epidural skctcods. 
P= pulse gene* atof. 
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2.6 NEUROMODULATION IN REFRACTORY ANGINA PECTORIS 
TENS and SCS were introduced in the early 1980s as a therapeutic option in severe angina 
pectoris.134'137,152 Although initially met by great scepticism, TENS and later SCS have gained 
acceptance as a therapeutic possibility in severe angina. To date, SCS in refractory angina pectoris 
is regarded as the most successful application of SCS. More than 80% of the patients experience 
pain relief in terms of less angina attacks and less consumption of short-acting nitrates.65,74'217 
Furthermore, the anti-anginal effect of SCS in refractory angina pectoris is due to decreased 
myocardial ischaemia during stimulation, rather than to an inhibition of the pain transmission. 
59,61,62,75,101,103,124,134,139,182,183 
Even if SCS and TENS have similar effects with regard to symptom relief, there are several 
practical issues regarding TENS treatment. The electrodes sometimes fall off and in 10-15% of 
the patients the electrodes causes skin irritation, which makes the method impractical for long-
term treatment. To date, TENS is mainly used in the screening process of angina pectoris, in 
order to determine whether the patient's chest pain is due to myocardial ischaemia and to 
determine whether the patient is sufficiently compliant to manage the SCS treatment adequately. 
In addition, TENS is also used alone in patients with anginal pain where SCS is not regarded as 
the optimum treatment for different reasons. In conclusion, SCS is a more suitable method for 
continuous treatment of angina pectoris, as it is a fully implanted system. 
2.6.1 SAFETY AND SHORT-TERM EFFECTS OF NEUROMODULATION 
When neuromodulation was introduced the safety of the treatment was a major concern. One 
concern was that the electrical stimulation in the vicinity of the heart would induce arrhythmias. 
This was shown not to be the case as long-term ECG studies (Holter monitoring) demonstrated 
that arrhythmias were not increased during stimulation.61'75 
Another major concern was that neuromodulation might conceal symptoms of ischaemia and 
thus deprive the patient of a warning signal by solely inhibiting the pain signal. However, the 
long-term ECG studies showed that neuromodulation reduced the number of ischaemic attacks 
and several short-term experimental studies (described below) has shown that the mechanism of 
action by neuromodulation is rather an anti-ischaemic effect than a pain inhibiting effect.61'75 In 
addition, clinical studies have shown that SCS do not conceal symptoms of myocardial 
infarction.2" TENS has been demonstrated to reduce the number of episodes of silent ischaemia. 
in unstable angina pectoris.35 
A further concern has been whether SCS is feasible in patients with cardiac pacemakers: an 
increasing number of patients with cardiac disease are treated with cardiac pacemakers and SCS 
may be indicated also among these patients.67 One study has demonstrated that cardiac 
pacemakers and bipolar SCS can be safely combined in patients with refractory angina pectoris.72 
However, individual testing is mandatory to confirm safety in each patient and unipolar SCS 
should not be used in combination with cardiac pacemakers.72,177 
Results from animal studies have suggested that SCS might have a protective effect on the 
cardiomyocytes (for example a decrease in oxygen-dependent metabolism) as there are 
indications that SCS might induce protective effects in tissues totally deprived of their oxygen 
supply.8''"' In addition, there are data implying that SCS might induce modulation of neuronal 
activity within the heart, which in turn would protect the heart from arrhythmias and thus lead to 
less generalised ischaemic threat to the heart.24,87 
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However, the effect of neuromodulation in humans preceded animal experiments. Since 1982 
several studies have been publish on the short-term effect of TENS and SCS on the relationship 
between myocardial ischaemia and angina pain from different centres. 
59,61,62,75,96,101,103,124,134,136,137.139,182,183 Different methods for ischaeafflia provocation, for example 
bicycle ergometer exercise tests, pharmacological stress testing and atrial pacing have been used. 
Irrespective of the stress method used, the relationship between anginal pain and myocardial 
ischaemia is unchanged. In summary, the results from these studies indicate that stimulation does 
not induce any changes in coronary haemodynamics or myocardial metabolism at rest (Fig 2). At 
a comparable stress level during stimulation, myocardial ischaemia and anginal pain disappears. 
However, at maximum stress level myocardial ischaemia and anginal pain reoccurs. Thus, 
myocardial ischaemia during stimulation induces anginal pain and the patient is not deprived of 
the warning signal. 
As earlier discussed, the two main determinants for myocardial ischaemia is coronary blood flow 
and myocardial oxygen consumption. Hence, the anti-ischaemic effect of neuromodulation 
should affect either, or both of the main determinants. 
Angina 
Aneina anoina Ischemia 
Results from invasive 
studies using intra 
coronary Doppler 
technique are 
contradictional. The 
results from one report 
indicated a general 
decrease in the coronary 
blood flow velocity by 
TENS treatment at 
rest.50 However, these 
findings have never 
been reproduced in later studies.'30'183 According to experimental studies, the anti-ischaemic effect 
of TENS and SCS at comparable stress level seems rather to be secondary to decreased 
myocardial oxygen consumption, than to an increase in myocardial blood flow.136"13' 
The mechanism behind the reduced oxygen consumption during stimulation has not yet been 
fully elucidated. Animal studies have indicated the existence of local opioid receptors in the 
myocardium. Agonistic effects on the opioid receptors will give rise to decreased myocardial 
oxygen consumption.44 Beta-endorphin is a highly selective endogenous fi-agonist. In one report, 
it was shown that myocardial extraction of beta-endorphin during control session was turned into 
release during SCS stimulation, indicating that this release of beta-endorphin might contribute to 
the decreased myocardial oxygen consumption via agonistic effects on the [a.-receptor.76 
Studies on heart rate variability and invasive studies on catecholamine release from the coronary 
circulation indicates that that SCS do not have any effect on the local effects on sympathetic 
activity in the myocardium..21'1"2'13 However, it has been demonstrated that general sympathetic 
activity is decreased during stimulation, which might be beneficial in terms of reducing the 
oxygen demand. l37'184 
There are conflicting results regarding SCS's effect on myocardial perfusion during stress, by 
means of positrion emission tomography. In one study, no effect of SCS on the myocardial 
perfusion could be demonstrated.59 Results form another study was interpreted by the authors as 
Ischemia No ischemia 
Neuromodulation 
FIGURE 2. "Ischaemic shift". SCS elevates the ischaemic threshold. 
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SCS altering the perfusion to benefit the ischaemic regions, even in the absence of increased total 
blood flow, i.e. a "homogenisation" of the coronary blood flow was induced during 
stimulation."" 
In summary, SCS seems to act by inducing a shift of the ischaemic threshold to higher levels of 
myocardial performance. This phenomenon is referred to as "ischaemic shift". The mechanism is 
not fully elucidated but seems to mainly depend on a reduction of myocardial oxygen 
consumption although several mechanisms might contribute to the effect involving changes in 
myocardial blood flow and neurohormonal mechanisms. 
2.6.2 LONG-TERM EFFECTS OF NEUROMODULATION 
Several reports of the long-term effects of SCS in severe angina pectoris have been published. 
They have shown positive effects on symptoms in terms of decrease of anginal attacks, 
improvement of quality of life as well as beneficial effects on myocardial ischaemia.65^6'176^183-217 
However, many of these studies have drawbacks such as a limited number of patients, short 
follow period and lack of randomisation. To date, no study has indicated that a prognostic 
benefit of SCS treatment. Hence, SCS can not replace any of the pharmacological or invasive 
therapies above that have been shown to produce prognostic benefit. 
2.6.2.1 The ESBY study 
Before the ESBY study (Electrical Stimulation versus Coronary Artery Bypass Surgery in Severe 
Angina Pectoris) was initiated, SCS had only been used to treat angina in patients who were 
rejected for revascularisation. The aim of the ESBY study was to compare the results of SCS 
treatment with CABG in patients with severe angina (CCS class 3 or 4) and increased surgical risk 
who were accepted for CABG on a strict indication of symptom relief, i.e. with no anticipated 
prognostic benefit from CABG.140 
Over a period of three years, 1992-1995, 104 patients were randomised to SCS (n=53) or CABG 
(n=51). After six months of follow-up, both groups showed an improvement in angina 
symptoms in terms of fewer anginal attacks and reduced consumption of short-acting nitrates 
(p<0.0001), without any differences between the groups. The SCS group had lower 
cerebrovascular morbidity (p=0.03) than the CABG group, but there were no differences 
between the groups with regard to cardiac morbidity. At the six-month follow-up, the SCS group 
had a lower mortality rate (p=0.02): one patient died in the SCS group compared to seven in the 
CABG group.140 
After six months, during bicycle ergometer tests, there was a decrease in myocardial ischaemia in 
the CABG group in contrast to the SCS patients, where no significant ischaemic changes at 
comparable stress level were detected. However, the SCS patients had their stimulators "off' 
since 24 hours before the stress tests. The reason for this was to investigate potential long-term 
anti-ischaemic effects of SCS without ongoing stimulation, as the actue effects during stimulation 
had been appropriately addressed in previous studies. However, a long-term effect of SCS could 
not be demonstrated. Hence, continuous active treatment is needed to obtain the positive effects 
of SCS on myocardial ischaemia. 
Furthermore, the ESBY patients were assessed with regard to quality of life, after six months of 
follow-up and after 4.8 years. '1 Quality of life was assessed using generic and disease-specific 
quality of life questionnaires. On both these occasion, quality of life was improved compared 
with before the intervention, with no differences between the groups (p<0.001). Furthermore, 
24 
there were no differences between the groups with regard to mortality after 5 years, 13 patients in 
the SCS group had died compared to 16 patients in the CABG group.73 
The conclusion from the results of the ESBY study was that SCS may be a therapeutic alternative 
for patients with severe angina and increased risk of surgical complications in connection with 
CABG. 
As all the patients in the ESBY study were considered eligible for CABG, they were not suffering 
from refractory angina pectoris. The possible symptomatic improvement from surgery must be 
related to the risk associated with the intervention. Table 2 describes patient groups in relation to 
prognostic and symptomatic aspects of CABG, possibilities of intervention and surgical risks. 
Group "A" are patients with an anticipated prognostic benefit from CABG according to the 
guidelines, "B" have only symptomatic indications, "C" have a risk of adverse outcome after 
CABG (i.e. the ESBY patients), and "D" are refractory angina patients.16'71,91 
TABLE 2. Parient groups in relation to prognostic and symptomatic aspects of CABG, 
as well as possibility of intervention and surgical risks. 
Patient group A B C D 
Prognostic benefit + 
Symptomatic indication +/- + + + 
Revascularisation possible + + + 
Increased surgical risk -/+ - + -/+ 
CABG indicates coronary artery bypass grafting. 
2.7 CONCLUDING REMARKS 
The prevalence of refractory angina pectoris is so far unknown. This patient group has not been 
described in terms of co-morbidity and the reasons for rejection for further revascularisation 
have not been systematically characterised, in terms of concomitant diseases as well as extent of 
CAD. Furthermore, there are no data available regarding the prognosis, progress of angina 
symptoms or quality of life in patients with refractory angina pectoris. Studies are therefore 
needed to explore and describe this patient group, as the number of patients with refractory 
angina seems to increase due to improved secondary prevention of CAD. 
Most of the previous studies regarding the long-term effect of SCS suffer from drawbacks in 
terms of being, retrospective, limited in size and/or non-randomised. Consequently, to evaluate 
the safety and long-term effects of SCS, systematic follow-up assessments are needed. The long-
term safety aspects of SCS include mortality, hospitalisations, cerebral complications and 
treatment complications. In addition, the health care costs of long-term SCS treatment need to be 
described. 
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3. AIMS OF THE THESIS 
The general aims of the thesis were to study the epidemiological characteristics of patients with 
refractory angina pectoris and to assess the applicability of SCS in patients with severe angina 
pectoris, with special attention to safety and long-term efficacy. More specifically, the aims can be 
defined as follows: 
• To estimate the incidence of refractory angina pectoris in a defined geographic area; 
• To describe the reasons why patients with refractory angina pectoris are considered 
inappropriate for further revascularisation; 
• To characterise patients with refractory angina pectoris in terms of general health 
characteristics, concomitant diseases, previous and ongoing treatment as well as extent of 
CAD; 
• To describe the progress of refractory angina pectoris with regard to fatality, cerebrovascular 
morbidity, angina symptoms and quality of life; 
• To study the safety aspects of SCS in terms of cerebral complications, treatment 
complications and causes of death; 
• To study the long-term effects of SCS with regard to morbidity and health care costs. 
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4. METHODS AND METHODOLOGICAL CONSIDERATIONS 
4.1 EPIDEMIOLOGICAL ESTIMATIONS (PAPER I AND II) 
According to the report by the European Society of Cardiology's (ESC) joint study group on the 
treatment of refractory angina pectoris, refractory angina pectoris is defined as severe stable 
angina pectoris (CCS class 3-4) in the presence of CAD that cannot be controlled by 
conventional pharmacological treatment and that is not available to further revascularisation. In 
addition, the decision that the patient is inappropriate for further revascularisation should be 
made on the basis of a recent coronary angiogram."3 
According to this definition, only patients with severe angina pectoris who undergo coronary 
angiography and are subsequendy considered inappropriate for revascularisation can be 
considered to suffer from refractory angina pectoris. Hence, follow-up of revascularisation 
conferences, where an interventional cardiologist and a cardiac surgeon evaluate the coronary 
angiograms and decide whether revascularisation is appropriate or not, would make it possible to 
identify patients fulfilling the criteria for refractory angina pectoris (Table 3). This would provide 
an estimate of the incidence of refractory angina pectoris in the catchment area of the 
participating centres. The letter of referral for coronary angiography should contain all the 
relevant data regarding the patient's general health status and any concomitant diseases. By 
obtaining this information from the patients' medical records it would be possible to characterise 
this patient group. Patient telephone interviews, performed by a research nurse, would also give 
complementary information. Further information regarding the characteristics of this patient 
group could be obtained by comparing the patients with refractory angina pectoris with patients 
with angina pectoris who were accepted for revascularisation. Thus, the refractory patients were 
matched by age and gender to a group of patients with severe stable angina pectoris (CCS class 3-
4), and CAD, who were accepted for revascularisation after the revascularisation conference. 
TABLE 3. Inclusion criteria for the patients in t he studies in Paper I and II. 
Criteria Refractory Revascularisation 
group group 
History of stable angina pectoris, CCS class 3-4 Yes Yes 
CAD on a recent coronary angiogram Yes Yes 
Accepted for further revascularisation after No Yes 
revascularisation conference 
Patient consent Yes Yes 
CAD indicates coronary artery disease; CCS, Canadian cardiovascular society. 
There is most likely a number of patients who suffer from severe angina pectoris, despite 
optimum pharmacological treatment, who are not referred for coronary angiography at all. These 
patients might fulfil the criteria for refractory angina pectoris, provided they undergo a coronary 
angiography, but they are disqualified a priori due to concomitant disease and/or advanced age. It 
is also known that acute angiographies are not reported at the revascularisation conferences. This 
means that an acute event in a patient with possible refractory angina pectoris may occassion an 
27 
acute coronary angiography, which may not be evaluated according to the routines for stable 
angina pectoris. 
However, as a recent coronary angiography is necessary to establish the diagnosis refractory 
angina pectoris according to the current definition by the ESC, this approach would be the most 
appropriate in order to obtain an estimate of the incidence of refractory angina pectoris. 
4.2 ASSESSMENT OF CORONARY ANGIOGRAPHIES (PAPER I AND II) 
In order to verify the presence of CAD in patients with angina pectoris and to assess whether a 
revascularisation procedure is appropriate, a coronary angiography is usually performed. If a 
lesion is present a qualitative assessment is made, involving grading of the diameter stenosis, in 
order to assess the lesion's impact on the coronary blood flow and, ultimately the myocardial 
perfusion. Despite the shortcomings of visual assessment of coronary angiographies (as 
previously discussed), this method is the most feasible to assess the overall distribution and 
severity of CAD, especially in a retrospective analysis. For this purpose scoring systems have 
been developed taking into account both severity of and distribution of stenoses within the 
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coronary tree. ' 
Thus, in order to characterise the refractory patients with regard to extent of CAD, the coronary 
angiograms were scrutinised by one of two experienced interventional cardiologists. The 
epicardial arteries were divided into 18 segments, based on the classification by Austen et al., and 
were evaluated as to the presence of lesions.26 If a lesion was present, visual qualitative 
assessment was carried out with grading of the diameter stenosis (DS) as "insignificant stenosis" 
(<50% DS), "significant stenosis" (>50%), "severe stenosis" (>70%DS or >90%DS) or "total 
occlusion" (100% DS and Thrombolysis In Myocardial Infarction (TIMI) flow grade 0 or l).8 
Five different scores were used for assessing the extent of the CAD and the subsequent impact 
on myocardial perfusion: 
The stenosis score is a description of the extent of the CAD and assesses the number of segments 
with significant stenoses as well as non-significant stenoses (not only stenoses >70%). All 
segments present are assessed and the score is adjusted for the stenosis grade. A disadvantage of 
the stenosis score is that the location of the stenoses is not taken into account by the scoring 
system. 
The l^ eaman coronary score is a continuous score that assesses the severity of the underlying CAD 
based on the fact that different coronary vessels carry different volumes of blood to the left 
ventricle.125 The more severe the stenosis and the larger the blood volume provided by the vessel 
to the left ventricle, the higher the coronary score. The Leaman score is weighted for the location 
as well as the grade of the stenoses, relating the impact of the stenoses to subsequent prognosis. 
However, not all coronary segments are assessed in this score and only stenosis >70% are 
assessed. In addition, the score does not assess whether or not all three main vessels are affected. 
However, the score has been validated and found to correlate to prognosis of the distribution of 
CAD on a population level. 
The coronary angiograms were also assessed according to the modified Duke coronary anatomy score 
described by Jones et al."3 The score is divided into nine prognostic groups representing a 
continuum of one-vessel, two-vessel, and three-vessel CAD, with the greatest emphasis laid on 
the presence of lesions in the LAD. As the Leaman score, the Duke score has been validated and 
found to correlate to prognosis of the distribution of CAD on a population level. The score is 
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weighted with regard to stenosis in LAD, but the location of the stenoses in other segments is 
not taken into account. Furthermore, all segments are not evaluated and only stenoses >70% are 
assessed. 
More than half of the patients in the refractory group had previously undergone CABG. Thus, in 
order to be able to assess the burden of CAD in patients with prior CABG, a score modified 
from the Duke coronary anatomy score was used. In this modified Duke score for previously CABG-
operatedpatients, the lesions were adjusted for the current result of any previous CABG. In this 
modified score, a lesion is disregarded if the periphery of the artery is supplied by a graft without 
a stenosis. 
According to clinical experience, peripheral stenoses are one of the main anatomical reasons for 
rejection for further revascularisation. As none of the scoring systems specifically assess 
peripheral stenoses, the peripheral stenosis score was developed as a modification of the stenosis 
score. The peripheral stenosis score only assesses whether there is a lesion in the peripheral 
segments of the coronary arteries and the grade of the stenosis is not taken into account. 
4.3 ASSESSMENT OF QUALITY OF LIFE (PAPER II) 
Quality of life is defined as the subjective perception of the degree of physical, psychosocial and 
social well-being. It is recommended that patients suffering from specific diseases should be 
assessed using two different kinds of questionnaires: generic and disease specific. Generic 
questionnaires measure health-related quality of life (HRQOL) in general.' They are designed to 
assess health-related quality of life in different patient groups as well as in healthy populations. 
Any disease can be evaluated using generic quality of life questionnaires. However, changes in 
specific symptoms may not be detectable with these instruments.64 On the other hand, disease-
specific questionnaires measure the impact on quality of life of a specific disease. These 
instruments are not applicable to other patient groups or healthy subjects, but they are more 
sensitive to changes in symptoms of a specific disease over time. 
Quality of life questionnaires have to be carefully validated to ensure their accuracy.64'197,201,210 
Three factors are of importance when evaluating the validity of a quality of life questionnaire: 
1. The instrument's discriminative ability, i.e. the ability to distinguish between different patient 
groups. 
2. The reliability/stability of the instrument, i.e. consistent results in repeated measurement.. 
3. Sensitivity to change/the evaluative ability, i.e. adequate detection of change in relation to an 
intervention. 
Furthermore, as the validation of quality of life questionnaires is a lengthy process, choosing one 
of the most frequently used questionnaires is recommended. 
The SF-36 is a generic health status questionnaire. It is a validated, well-known and widely used 
generic health status questionnaire.48'64'2111'212 The 36 items in the questionnaire are grouped into 
eight scales: physical functioning, social functioning, role limitations caused by physical problems, 
role limitations caused by emotional problems, mental health, energy/vitality, bodily pain, and 
general health. However, the SF-36 is generic, i.e. not disease-specific, and may thus fail to 
discriminate between classes of angina, and may be insensitive to changes in cardiovascular 
health.66'197 
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The SAQ is a disease-specific quality of life questionnaire assessing the functional status of 
patients with angina pectoris. The questionnaire consists of 19 items measuring five dimensions 
of CAD: physical limitation (how daily activities are limited by symptoms of CAD), anginal 
stability (assesses change in angina symptoms at the most strenuous level of activity), anginal 
frequency (frequency of angina episodes and consumption of short-acting nitrates), treatment 
satisfaction, and disease perception (assesses the burden of the CAD on the patient's quality of 
life). The result for each patient comprises five separate scores, one for each dimension, in a 
range from zero to 100. The SAQ has been used in several follow-up studies of angina pectoris 
patients to assess benefits from interventions but also to assess symptomatic changes in patients 
with stable angina pectoris.36'195"197 
The CHP is a disease-specific, HRQOL questionnaire, tested for reliability and validity in a 
Swedish population with ischaemic heart disease.210 The questionnaire consists of three parts. In 
part I, the presence and degree of angina pectoris according to the CCS classification are assessed 
by the patient. Part II assesses HRQOL (16 items) and part III is disease-specific assessing quality 
of life with regard to angina pectoris. Four factors have been extracted: Emotional, Social, 
Somatic functioning and Emotional Control. The second and third parts of the CHP consist of a 
visual analogue scale with verbal "anchors" at each side expressing the extremes. The scores in 
part II and III are summed up and divided by the number of answered items. Low values indicate 
a better quality of life. The CHP has been used for assessing benefits from interventions.210 
In contrast to the SAQ, the CHP questionnaire describes the impact of angina pectoris on the 
emotional and social aspects of quality of life, whereas the SAQ rather describes the impact on 
function of the angina symptoms. However, the CHP questionnaire is less frequendy used than 
the SAQ. 
4.4 CEREBROVASCULAR MORBIDITY AND WHITE MATTER DISEASE (PAPER III) 
Neurological and neuropsychological complications frequently occur in connection with CABG. 
42,143,155,173,190,202 prevjous studies have indicated that there is a relationship between subcortical 
brain ischaemia (white matter disease, WMD), caused by small-artery disease in the brain, and 
neuropsychological decline after CABG.52'80'82,92'167'17" Ischaemic WMD is visible on T2-weighted 
magnetic resonance images as signal hyperintensities in the brain's white matter. Post-mortem 
examinations have shown that the grade of magnetic resonance imaging (MRI) hyperintensities 
corresponds to the severity of ischaemic tissue damage.81 
In the study presented in Paper III, neurological complications were defined as focal cerebral 
ischaemia, i.e. stroke and/or transient ischaemic attacks (TIA). The diagnoses of stroke and TIA 
were classified according to the criteria presented in the report by the WHO Task Force on 
Stroke and Other Cerebrovascular disorders.10 The neurological examinations were performed by 
one and the same experienced neurologist before and six months after the primary intervention 
(i.e. CABG or SCS). 
Neuropsychological complications were defined as presence of astheno-emotional disorder 
(AED). The AED diagnosis is validated and has a high inter-rater reliability.174,175 Symptoms of 
AED; enhanced psychic fatigability, diminished power of concentration, amnaesic problems, 
irritability and emotional instability, were identified during the neurological examination.46'130,174'175 
The symptoms of AED must not be secondary to a depressed mood disorder. Each symptom 
was judged separately and graded as "non-existent to a pathological extent" or "existent to a 
moderate to severe extent". If all symptoms were present to a "moderate to severe extent", the 
patient was considered to have AED. Furthermore, neuropsychological function was also 
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assessed in the patients pre- and post-operatively by means by a battery of 14 neuropsychological 
tests. The tests encompass encompassing attention, memory functions and psychomotor 
performance, a simple reaction time test and Trail Making Tests A and B.199 The tests were 
performed by a licensed neuropsychologist. 
Presence of WMD before intervention was identified by cerebral magnetic resonance imaging. 
MRI examination before treatment was planned for all the patients. All examinations were 
performed on a 0.5 Tesla magnet (Philips Gyroscan NT5, Eindhoven, the Netherlands). The 
protocol included a double spin-echo sequence. The slice thickness was 7 mm in the axial 
projection and the in-plane pixel size was 0.9 x 0.9 mm. 
Fazekas' rating scale was used to grade the lesion load of MRI hyperintensities in the white 
matter of the brain.80'82 Fazekas' rating scale has been developed as a simple method for 
classification of the hyperintensities on MRI to reflect the severity of the WMD.80 The MRI 
hyperintensities are rated as punctate, early confluent and confluent lesions. 82 The Fazekas' rating 
scale is a well-known and validated method for grading WMD, but a disadvantage of the scale is 
that it does not differentiate between the causes of the lesions 82'11"1" The presence and grade of 
the WMD according to Fazekas' rating scale were assessed before intervention by one and the 
same neuroradiologist, who was blinded to the treatment allocation. The WMD was defined as 
punctate foci of MRI hyperintensities, beginning confluence of foci and large confluent areas. 
The MRI changes according to Fazekas' rating scale might be due to "pure" WMD, but also to 
cerebral infarctions or to non-specific periventricular changes around the posterior horns, a 
common finding in the elderly.144 To be able to relate "pure" WMD to cerebral complications, 
one and the same neuroradiologist scrutinised the white matter changes to exclude isolated 
periventricular areas around the posterior horns and focal solitary infarctions. In this manner a 
"modified" Fazekas' rating scale was obtained for the evaluation of the patients. 
4.5 MORTALITY AND CAUSES OF DEATH (PAPER II AND IV) 
Data on mortality and causes of all deaths in Sweden are continuously collected by the Centre of 
Epidemiology at the Swedish National Board of Health and Welfare. The rate of missing data on 
causes of death in this register is claimed to be 0.6%.' 
The cause of death is established by clinical examination by a physician or by autopsy. The 
number of autopsies in Sweden has decreased from about 50% at the beginning of the 1970s to 
about 15% in 2001. The decrease varies with different age. Among patients over 85 years of age 
the number has decreased by about 85%, from 30% in 1970 to 4% in 2001. Consequently, the 
examinations made to define the underlying causes of death are a source of unreliability. 
Data regarding the cause of death and death dates were obtained from the cause of death register 
for the patients participating in the ERA study (Paper II) and for the ESBY patients (Paper IV). 
4.6 HEALTH CARE COSTS AND HOSPITALISATION (PAPER IV) 
The Centre of Epidemiology at the Swedish National Board of Health and Welfare also 
continuously collects data on hospitalisations and surgical interventions carried out in Sweden.2 
The rate of missing data on hospital admissions in this register is claimed to be less than 2% and 
missing data on diagnosis less than 1%. Data from this register were collected for the patients 
participating in the ESBY study (Paper IV). In addition, data on costs and days in hospital in 
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connection with the primary intervention were collected prospectively from the hospital 
databases by a hospital economist. In order to assess the costs incurred by each hospitalisation, a 
certain amount was ascribed to each in-patient-day in the accounts. Interventions due to coronary 
heart disease, i.e. angiography, PCI, CABG, SCS implantation and re-operations related to SCS 
were also accounted for. 
As the ESBY patients were recruited from different parts of western Sweden, with a variety of 
approaches to out-patient care, nursing-home stay and medication data regarding these costs 
were not collected. Even though information about these costs would have been of interest, the 
data would have been inconsistent in terms of quality. 
In order to further estimate the cost of the SCS treatment, the pulse generator life span was 
analysed for up to five years after implantation. The pulse generator life span was calculated from 
implantation until either the pulse generator had to be replaced or the last occasion of active 
stimulator function noted in the patient file. 
4.7 LONG-TERM EFFICACY OF SPINAL CORD STIMULATION (PAPER IV) 
Information regarding treatment effect, need for intervention to restore stimulator function and 
treatment complications (i.e. infections, electrode fractures and electrode displacements) could be 
obtained for all patients treated with SCS in the ESBY study, as they were all regularly followed 
up at the Multidisciplinary Pain Centre at Östra Hospital, Göteborg. 
4.8 SURGICAL TECHNIQUES (PAPER III AND IV) 
The CABG operations were performed as open-heart surgery with extracorporeal circulation 
according to the standard clinical practice during the study period. The cardiopulmonary bypass 
circuit included a membrane oxygenator and non-pulsatile flow during bypass, typically 2.4 l/m2 
of body surface area per minute (reduced to 2.0 l/m2 per minute during hypothermia). The mean 
arterial pressure was maintained in the range of 50-70 mmHg. Hypothermia (28-32°C) and 
cardioplegia were applied. The duration of extracorporeal circulation, aorta cross-clamping, 
surgery and anaesthesia were monitored and related to the development of cerebral 
complications. 
The patient is awake and placed in a prone position during SCS implantation. An incision is made 
at the mid-thoracic level after administration of local anaesthesia. The epidural space is identified 
and punctured using a Touhy needle. A quadripolar electrode is introduced through the needle 
into the epidural space and is guided to the level of the Thl-Th2 vertebrae during X-ray 
monitoring. The electrode is placed at the midline and the patient experiences paraesthesiae 
during the intraoperative test stimulation. It is important to adjust the position of the electrode so 
that the paresthesiae in the chest cover the area to which the patient localises the anginal pain. 
This is to ensure that the area of the spinal cord innervating the heart is stimulated. When 
adequate paraesthesiae are obtained, the electrode is fixed to the ligaments and an extension wire 
is tunnelled subcutaneously to below the left costal arch, where it is connected to a subcutaneous 
pulse generator.74 The system is fully implanted and is programmed telemetrically (Fig 1). The 
treatment is completely managed by the patient, who can switch on and off the stimulation as 
well as regulate the amplitude (within preset limits). In the present studies, all patients had 4-polar 
epidural electrodes. The SCS systems used were all Medtronic Itrel pulse generators (model II or 
III), connected to an epidural 4-polar Pisces Quad electrode (Medtronic, Minneapolis, MN, 
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USA). Implantation is usually performed by a neurosurgeon or an anaesthesiologist, the latter 
being the case in Göteborg. 
4.9 STATISTICAL METHODS 
In Paper I, paired non-parametric tests were used when comparing the two groups, i.e. the 
Wilcoxon Sign Rank Test and the Sign Test were used for analysing continuous and categorical 
variables respectively. When these tests were not applicable, the Mann-Whitney U test and the yl 
test were used. Non-parametric test were used since the data had a skewed distribution. Paired 
tests were used as they are considered to be more reliable than non-paired tests.18 
In Paper II, survival analysis was performed using Kaplan-Meier probabilities, employing the log-
rank test. Paired non-parametric tests were used when comparing the two groups, i.e. the 
Wilcoxon Sign Rank Test and the Sign Test were used for analysing continuous and categorical 
variables respectively. When these tests were not applicable, the Mann-Whitney U test and the yl 
test were used when comparing the two groups with regard to quality of life data, anginal 
function class, extent of CAD, cerebral morbidity and pharmacological treatment. Non-
parametric test were used since the data had a skewed distribution. Paired tests were used as they 
are considered to be more reliable than non-paired tests. 18 
In Paper III, non-parametric tests were used due to the small number of patients and events.18 
Categorical data were analysed using tests and Fisher's exact test: relative risk and 95% 
confidence intervals (CI) are quoted. Continuous variables were analysed using the Mann-
Whitney-U test. The data were analysed on an intention-to-treat basis. 
In Paper IV, the Mann-Whitney U test was employed compare the costs of the treatment groups 
and the number of hospital days, as these data had a skewed distribution.18 The Fisher's exact test 
was used to analyse differences in the number of events and causes of death, as the event were 
few. The data were analysed on an intention-to-treat basis. 
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5. PRESENTATION OF THE STUDIES 
5.1 PAPER I 
Incidence, Clinical and Angiographic Characteristics of Patients with Refractory Angina 
Pectoris - the Epidemiological study of Refractory Angina pectoris (ERA) 
BACKGROUND AND DESIGN 
The epidemiology of refractory angina pectoris is virtually unknown. However, according to 
previous estimations, a considerable number of patients may suffer from this condition. The aim 
of the study was to assess the incidence of refractory angina pectoris and to characterise the 
patient group in terms of concomitant diseases, treatment and angiographic findings. This was a 
multicentre observational study, with seven participating centres. Patients who underwent 
coronary angiography but were considered inappropriate for further revascularisation (i.e. 
coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI)) despite 
severe stable angina pectoris of Candian Cardiovascular Society (CCS) class 3-4 were included in 
the study. The refractory patients were matched by gender and age to a group of patients with 
coronary artery disease (CAD) and severe angina pectoris who were accepted for 
revascularisation after angiography. The two patient groups were compared with regard to health 
history, concomitant diseases, previous and current treatment. The extent of CAD on the 
coronary angiograms was also assessed using the stenosis score, the peripheral stenosis score, the 
Leaman coronary score, he Duke coronary score and the Duke coronary score modified for 
previous CABG. 
RESULTS 
During the inclusion period of three years, 146 patients with refractory angina pectoris were 
identified and evaluated at the revascularisation conferences at the seven participating centres. 
This number corresponds to 2.1% of all patients who underwent coronary angiography due to 
angina pectoris and were evaluated at the revascularisation conference (1% of all patients 
undergoing angiography also including angiographies for emergency reasons). 
The refractory group had more pronounced cardiac disease than the revascularisation group. 
More patients in the refractory group had CCS class 4 (27% vs. 16%), had previously suffered 
one or more myocardial infarctions (26% vs. 13%), had undergone a previous revascularisation 
procedure (CABG and/or PCI) (63% vs. 21%) and/or had pharmacologically treated heart 
failure (19% vs. 6%) than the patients in the revascularisation group. Furthermore, the average 
left ventricular ejection fraction was lower in the refractory group than in the revascularisation 
group (0.52 vs. 0.59). In 38% of the patients, current myocardial ischaemia had not been 
confirmed before angiography. The majority of patients in both groups received beta-blockers, 
short-acting nitrates and aspirin, while only about one fourth of patients received calcium 
antagonists. 
A considerable number of the patients had extracardiac disease such as diabetes, obstructive 
pulmonary disease of clinical importance and cerebrovascular disease, with no differences 
between the groups, except for insulin-treated diabetes (20% vs. 6%) and renal dysfunction (15% 
vs. 3%), which were more common in the refractory group than in the revascularisation group. 
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More patients in the refractory group than in the revascularisation group had three-vessel disease 
(59% vs. 39%). The mean stenosis score (1.6 vs. 1.0) and the number of significant stenoses (5.1 
vs. 4.1) were higher in the refractory group compared with the revascularisation group. 
Furthermore, the patients in the refractory group had a higher peripheral stenosis score (0.37 vs. 
0.20). The refractor}' group had also a higher Leaman coronary score (17.7 vs. 9.4) and Duke 
coronary score (6.4 vs. 4.5) than the revascularisation group. However, when the Duke coronary 
anatomy score was adjusted for previous CABG, there was no difference between the groups. 
One of the most important issues concerning the patients with refractory angina is the reason 
why they are rejected for further revascularisation. In the present study, the most common 
reasons for rejection were unsuitable coronary anatomy and a potential risk of damaging pre­
existing graft. However, in patients with no previous CABG, unsuitable coronary anatomy in 
combination with extracardiac diseases was the most common cause of rejection. 
LIMITATIONS OF THE STUDY 
Since the study inclusion period was limited to three years, only a limited number of patients 
were included in the study. The incidence of refractory angina pectoris may be underestimated in 
this study, possibly due to the fact that only patients evaluated at the revascularisation 
conferences were not included. 
CONCLUSIONS 
A considerable number of patients seem to suffer from refractory angina pectoris. Compared 
with patients accepted for revascularisation, the patients with refractory angina pectoris have 
more pronounced CAD as well as cardiac disease. Some of the patients appear to be in fairly 
good condition with respect to extracardiac health compared with revascularised patients. 
However, there seems to be a subpopulation in the refractory group with severe cardiac as well as 
extracardiac diseases. The main reasons why further revascularisation is not appropriate are 
unsuitable coronary anatomy and a potential risk of damaging pre-existing grafts. In addition, 
several patients were rejected for revascularisation due to concomitant severe extracardiac 
diseases, despite no previous heart surgery. A significant number of patients showed no recent 
evidence of current myocardial ischaemia, which could be considered a prerequisite for referral 
for coronary angiography in most cases. Furthermore, there are probably a number of patients 
who would benefit from optimised medication. 
5.2 PAPER II 
Fatality, Morbidity and Quality of Life in Patients with Refractory Angina Pectoris — A 
One Year Follow-Up of the ERA study 
BACKGROUND AND DESIGN 
Refractory angina pectoris is defined as severe angina pectoris (CCS class 3-4) due to coronary 
artery disease that cannot be controlled by pharmacological or invasive therapy. To date, the 
prognosis in refractory angina pectoris is unknown. The present study is a one-year follow-up of 
the patients in the so called ERA study (Epidemiologic study of Refractory Angina pectoris) 
aiming at assessing fatality, morbidity, development of anginal symptoms and quality of life. The 
quality of life was assessed by using one generic (Short Form 36; SF-36) and two disease-specific 
quality of life questionnaires (Seattle Angina Questionnaire; SAQ and Cardiac Health Profile; 
CHP). 
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RESULTS 
Fourteen patients in the refractory group died during the one-year follow-up period compared to 
one in the revascularisation group (pcO.OOl). More patients in the revascularisation group 
developed stroke or transient ischaemic attacks than the patients in the refractory group (12 vs. 3; 
p<0.05). The refractory group had a higher CCS class (p<0.0001) than the revascularisation 
group after one year of follw-up. 
Compared with the revascularisation group the refractory group had more impaired quality of life 
with regard to physical function, physical well-being and impact of angina symptoms. In contrast, 
there were no difference between the groups with regard to social function, emotional function 
and mental health. When compared to a normative Swedish population, the refractory group had 
lower scores in all the dimensions of SF36 except for social function and mental health. 
However, compared to patients with fibromyalgia, the refractory group had a better quality of life 
in the dimensions of bodily pain, social functioning and mental health 
LIMITATIONS OF THE STUDY 
A limited number of patients were included in the study. In addition, one year of follow-up is a 
limited period of time. The CHP questionnaire is a validated questionnaire but has not been 
extensively used compared to SAQ and SF36. A limited number of patients in the refractory 
group answered the quality of life questionnaires at both of the two occasions. Furthermore, 
there was a limited number of matched controlled pairs who answered the questionnaires in both 
the refractory group and the revascularisation group. 
CONCLUSION 
Patients with refractory angina pectoris have a high fatality rate and their quality of life is 
markedly impaired compared with a group of patients with CAD who have undergone 
revascularisation. The quality of life of both these groups of angina pectoris patients seems to be 
largely linked to the patient's CCS class. The angina symptoms seem to inflict limitations of 
physical activity and impair physical well-being in the refractory group. However, social function, 
emotional function and mental health do not seem to be affected by the severity of the anginal 
pain. This is in contrast with patients with chronic pain syndromes, whose quality of life is 
severely impaired physically as well as mentally and socially. There are additional treatment 
modalities that may be appropriate for patients with refractory angina pectoris aiming at 
symptom relief and improvement in quality of life. 
5.3 PAPER III 
Deep White Matter Disease in Magnetic Resonance Imaging Predicts Neurological and 
Neuropsychological Complications after Coronary Artery Bypass Grafting 
BACKGROUND AND DESIGN 
The ESBY study (Electrical Stimulation versus Coronary Artery Bypass Surgery in Severe Angina 
Pectoris) included 104 patients with severe angina pectoris, increased surgical risk and, no 
prognostic benefit from revascularisation who were randomised coronary artery bypass grafting 
(CABG) or spinal cord stimulation (SCS). Cerebral complications in connection with SCS have 
previously not been described. Thus, the aim of the study was to assess neurological and 
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neuropsychological complications in CABG with those following SCS. An additional objective of 
the study was to assess whether preoperative white matter disease (WMD) might predict cerebral 
complications, as previous studies have shown that there is a relationship between WMD and 
neuropsychological decline after CABG. The WMD was identified by preoperative cerebral 
magnetic resonance imaging (MRI). Neurological and neuropsychological complications were 
assessed by the same experienced neurologist before and six months after intervention. 
RESULTS 
More patients in the CABG group than in the SCS group developed focal cerebral ischaemia 
(p<0.05) and astheno-emotional disorder (p<0.001). More patients with WMD undergoing 
bypass were affected by focal cerebral ischaemia (p<0.01) and astheno-emotional disorder 
(p<0.001) after the intervention compared to patients with WMD undergoing spinal cord 
stimulation. In patients with no WMD there were no differences between the CABG group and 
SCS group with regard to cerebral complications. 
LIMITATIONS OF THE STUDY 
The ESBY study was not blinded because the two procedures differ significantly, i.e. the 
treatment allocation was known by patient and the surgeon. Furthermore, the study included a 
limited number of patients. 
CONCLUSION 
White matter disease may be a previously unobserved surgical risk factor for cerebral 
complications. Patients with preoperative WMD developed cerebral complications to a higher 
extent following CABG than following SCS. Thus, presence of WMD might indicate an 
increased risk of cerebral complications for a patient after CABG. It may be valuable to perform 
a MRI and assess the extent of WMD before CABG and avoid surgery in patients with WMD, to 
prevent cerebral complications. Further studies are needed to evaluate the predictive potential of 
WMD. The present study further supports the results from the ESBY study; that SCS might be a 
therapeutic alternative in patients with severe angina pectoris and surgical risk factors. 
5.4 PAPER IV 
Cost-Effectiveness of Spinal Cord Stimulation versus Coronary Artery Bypass Grafting in 
Patients with Severe Angina Pectoris - Long-term Results from the ESBY Study 
BACKGROUND AND DESIGN 
The ESBY study (Electrical Stimulation versus Coronary Artery Bypass Surgery in Severe Angina 
Pectoris) included 104 patients with severe angina pectoris, increased surgical risk and, no 
prognostic benefit from revascularisation who were randomised to coronary artery bypass 
grafting (CABG) or spinal cord stimulation (SCS). The aim of this study was to assess cost-
effectiveness of SCS and CABG in the patients participating in the ESBY study, since the cost-
effectiveness of SCS treatment compared with CABG previously not had been assessed. 
Furthermore, the study aimed at assessing morbidity and causes of death during two years of 
follow-up. The efficacy of SCS treatment and the complication rate of the treatment during the 
study period were also assessed. 
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RESULTS 
SCS proved to be a less expensive symptomatic treatment modality of angina pectoris than 
CABG (p<0.01). The SCS group had fewer hospitalisation days related to the primary 
intervention (p<0.0001) and fewer hospitalisation days due to cardiac events (p<0.05). The 
groups did not differ with regard to causes of death. There were no serious complications related 
to the SCS treatment. 
LIMITATIONS OF THE STUDY 
The limitations of the present study are identical to those of Paper II, i.e. the ESBY study was 
not blinded because the two procedures differ significantly, i.e. the treatment allocation was 
known by patient and the surgeon. Furthermore, the study included a limited number of patients. 
CONCLUSION 
Previous studies have shown that SCS is effective at relieving myocardial ischaemia and severe 
angina pectoris. The present study suggests that SCS is a more cost-effective symptomatic 
treatment modality in angina pectoris than CABG in a selected patient group, i.e. patients with 
coronary artery disease, severe angina pectoris, no anticipated prognostic benefit from CABG 
and increased surgical risk. Taking into account that previously presented data from the ESBY 
study have found SCS and CABG to be comparable in terms of symptom relief, quality of life 
and survival, this study further supports the results from the ESBY study; that SCS may be a 
therapeutic alternative for these patients. 
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6. DISCUSSION 
6.1 INCIDENCE OF REFRACTORY ANGINA PECTORIS 
The majority of patients suffering from angina pectoris can be adequately treated by conventional 
pharmacological therapy and/or invasive therapy in terms of CABG and PCI. There are, 
however, patients who suffer from severe angina pectoris due to coronary insufficiency, despite 
optimum pharmacological treatment, and who are not accessible for any further revascularisation 
(refractory angina). It has been suggested that this patient group is increasing in number as a 
result of improved secondary prevention of CAD.135,188'213 
However, the epidemiology and the characteristics of this patient group have never been fully 
explored. Thus, one of the aims of the study presented in Paper I was to estimate the incidence 
of refractory angina pectoris in a def ined geographic area during a defined time period. The study 
confirms that there seems to be a considerable number of patients who suffer from refractory 
angina pectoris. 
Refractory angina pectoris is defined in the report by the ESC joint study group on the treatment 
of refractory angina.101 According to the report, the patient's angina symptoms have to be due to 
coronary insufficiency and the decision that the patient is inaccessible for further 
revascularisation procedures should be based on a recent coronary angiogram. Hence, the only 
way to obtain the diagnosis refractor}' angina pectoris is to undergo a coronary angiography and 
subsequently be considered inappropriate for further revascularisation. Thus, the method used in 
Paper I may be regarded as an adequate way to find patients fulfilling the criteria for refractory 
angina pectoris. Using this method to identify patients suffering from refractory angina pectoris 
in a defined area during a defined time period would consequendy provide an estimate of the 
incidence. 
As a recent coronary angiogram is needed to confirm the diagnosis refractory angina pectoris, a 
cross-sectional study in the population in order to estimate the prevalence would not be possible 
for ethical and practical reasons. Coronary angiography is associated with risks and should only 
be performed if considered necessary for further therapeutic intervention.58'112 
In earlier estimations, approximately 10% of all patients undergoing coronary angiography are 
rejected for revascularisation despite severe angina.4"'135 Compared with these estimations, the 
incidence of refractory angina pectoris found in the study in Paper I was low. There are reasons 
for a possible underestimation. An acute event in patients with possible refractory angina pectoris 
may necessitate an emergency angiography, which may not be evaluated according to the routine 
for stable angina pectoris, as emergency angiographies are rarely presented at the 
revascularisation conferences in the participating institutions. In addition, patients may have been 
accepted for revascularisation at the conference, but were in spite of this rejected later. On the 
other hand, the surgical and anaesthesiological management in relation to revascularisation 
procedures has improved since the mid-nineties, when one of the earlier estimations was made.40 
Hence, patients previously considered inappropriate for revascularisation, such as elderly patients, 
may now be available for revascularisation today.17'94 This development of the techniques 
involved in revascularisation has probably shifted the boundary between refractor)' and non-
refractory angina pectoris. In addition, during the last few years, the number of angiographies due 
to stable angina pectoris has been decreasing in Sweden.4'3 Instead, an increasing number of 
angiographies are preformed on the indication of unstable angina pectoris. Hence, the change in 
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the clinical management of angina pectoris is a contributing factor to the lower frequency of 
refractory angina pectoris reported in Paper I. 
According to the results of the study in Paper I, a considerable number of patients seem to suffer 
from refractory angina pectoris, approximately 2.5-3 persons per 100 000 inhabitants per year. 
This would correspond to approximately 250 patients per year in Sweden. The refractory patients 
comprised 1% of all patients undergoing angiography, including angiographies for emergency 
reasons, at the participating centres. 
There are probably patients suffering from disabling angina pectoris who are not referred for 
angiography at all, because of advanced age and/or concurrent diseases. According to clinical 
experience, patients suffering from obstructive pulmonary disease, renal failure and severe 
congestive heart failure may be found in this group. For some of these patients, the angiography 
itself may pose a risk of complications. These patients might suffer from refractory angina 
pectoris, but the diagnosis cannot be established as verification of CAD on a recent angiogram is 
not possible. Nevertheless, this patient group may be in need of additional symptom-relieving 
treatment modalities. 
6.2 CHARACTERISTICS OF PATIENTS WITH REFRACTORY ANGINA PECTORIS 
The patients with refractory angina pectoris seemed to have more pronounced cardiac disease as 
well as CAD, compared with the patients who were accepted for revascularisation. A 
considerable part, 54%, of the refractory patients had previously undergone CABG. When the 
extent of CAD was adjusted for previous CABG, there were no differences between the 
refractory angina patients and the patients accepted for revascularisation. Hence, patients with 
refractory angina pectoris have CAD which is as severe, or even more severe, than the patients 
accepted for revascularisation. In addition, the patients in the revascularisation group were not 
representative of the "ordinär}'" population undergoing revascularisation, which is generally 
younger and have less pronounced CAD. 
Even though the refractory group in Paper I had advanced CAD - 59% had three-vessel disease 
and 54% previous CABG - patients accepted for SCS treatment due to refractory angina seem to 
have even more severe CAD, according to previous studies. In populations of patients with 
refractory angina pectoris treated with SCS, 70-80% have three-vessel disease and 60-70% of the 
patients have previously undergone CABG procedure.65,206 Hence, patients who are referred for 
treatment with SCS seem to have even more severe CAD than the refractory patients identified 
after referral for coronary angiography. This might be secondary to the fact that the more 
progressive disease the disease of a patient, the greater the readiness to refer the patients for 
additional treatment. 
The reasons for rejection for revascularisation have previously not been systematically 
characterised. According to clinical experience unsuitable coronary anatomy, impaired LVEF and 
extracardiac diseases, such as obstructive pulmonary disease and renal failure, are the main 
reasons for rejection for revascularisation There were more patients with impaired LVEF, 
insulin-treated diabetes and renal dysfunction in the refractory group than in the revascularisation 
group, but there was no difference between the groups with regard to obstructive pulmonary 
disease or cerebrovascular disease. 
According to the study in Paper I the main reason for rejection was unsuitable coronary anatomy. 
In patients who had previously undergone CABG the main contributing factor was a potential 
risk of damaging pre-existing grafts and in patients who had not had previous surgery, 
40 
extracardiac disease was the main contribution factor. The anatomy was considered unsuitable 
due to multiple and peripheral stenoses and due to the localisation of the stenosis. This was 
confirmed by the scrutiny of the coronary angiograms, where the patients in the refractory group 
had a higher stenosis score as well as higher peripheral stenosis score than the revascularisation 
group. 
However, impaired LVEF does not seem to be a major cause of rejection. This might be 
explained by that the patients with the most impaired LVEF not being referred for coronary 
angiography at all. This may also be a possible explanation of the fact that few patients were 
diagnosed with obstructive pulmonary disease in the refractory group. 
According to the definition of refractory angina pectoris, presence of CAD is mandatory for the 
diagnosis.135 In the study in Paper I, patients were considered to have CAD if they had non­
significant or significant diameter stenosis in the epicardial vessels according to the medical 
records. There is an ongoing debate regarding about what extent of atherosclerosis in the 
coronary vessels that can be considered "normal" for age and gender and what should be 
considered CAD. In the present study, patients with non-significant stenosis were considered to 
suffer from CAD, as interobserver variability is known to be present and it has been shown that 
the maximum coronary flow may be affected by a constriction as small as 30%.93,221 
Previous CABG seems to be a factor that is crucial for whether or not further revascularisation is 
possible in patients with refractory angina pectoris. In approximately 40% of the patients, a 
potential risk of damaging pre-existing grafts, which may be functioning in some parts but 
occluded in other parts, is a contributing factor or the main reason why further revascularisation 
is considered inappropriate. 
6.3 MANAGEMENT OF REFRACTORY ANGINA PECTORIS 
In Paper I a majority of the patients received anti-anginal pharmacological treatment in the form 
of beta-blockers and nitrates. Only 26% of the patients in the REFRACT group were treated 
with calcium antagonists. The additional effect of a calcium antagonist to patients already 
medicated with beta-blockers has been demonstrated in exercise studies.88,123 Furthermore, the 
results from the ACTION study indicate that addition of calcium antagonists to conventional 
symptomatic treatment of angina pectoris may have long-term beneficial effects in terms of a 
reduction of the need for coronary angiographies and interventions."16 However, more studies are 
needed to confirm the beneficial effects of adding calcium antagonists to beta-blockers. Many 
patients do not tolerate triple therapy with beta-blockers, nitrates and calcium antagonists due to 
side effects. Nevertheless, calcium antagonists are an alternative for patients who do not tolerate 
beta-blockers.83'91,98Sixty-eight percent of all the patients were on lipid-lowering therapy, which is 
similar to the usage of lipid-lowering treatment in a population of patients with stable angina 
pectoris and that of a post-CABG population.3 7,166 However, this might be below optimum, 
considering the suggestion of the beneficial prognostic effect of statins. ACE inhibitors are not 
recommended to date in the treatment of refractory angina pectoris. Considering the frequency 
of heart failure and insulin-treated diabetes in the patients with refractory angina pectoris, there 
are probably subgroups of patients with refractory angina pectoris who might benefit from 
treatment with ACE inhibitors. 
Before referring a patient with stable angina pectoris for coronary angiography, optimisation of 
medication should be the first step, as coronary angiography and revascularisation procedures 
involve a certain risk of complications. In a previous study by Nägele et al. it was demonstrated 
that in 50% of patients with refractory angina pectoris partial symptom relief can be obtained by 
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optimisation of the pharmacological treatment.'34 However, that patient group's pharmacological 
treatment was not as optimised as that given to patients suffering from refractory angina pectoris 
presented in Paper I. 
The results of the study in Paper I indicated that there may be additional possibilities for 
optimisation of the pharmacological therapy, in both in the group of patients with refractory 
angina pectoris and to patients accepted for revascularisation. 
It is also of importance to establish myocardial ischaemia as the cause of chest pain before 
referring the patient for a coronary angiography. In the study in Paper I, approximately 40% of 
all the patients had no any verified myocardial ischaemia on stress tests before being referred for 
coronary angiography, which may be considered quite remarkable. The patients were probably 
referred for a coronary angiography based on a history of known CAD and/or previous evidence 
of myocardial ischaemia. Nevertheless, some of the patients, in both the refractory and the 
revascularisation group, may have had chest pain of other origin, such as gastro-oesophageal 
disorders, which may be difficult to distinguish from patients with chest pain secondary to 
myocardial ischaemia.33'34'11 Even though the patients have known CAD or previously 
demonstrated myocardial ischaemia, the current chest pain may be due to other causes or the 
patient may suffer from two diseases that both give rise to chest pain. 
Bicycle ergometer/treadmill tests have low sensitivity for different reasons as described in the 
introduction. Pharmacological stress tests, such as myocardial perfusion scintigraphy or stress 
echocardiography, may be more suitable for the evaluation of ischaemia in this patient group. 
Even if these stress tests are more sensitive than exercise tests in this patient group, a negative 
stress test does not exclude myocardial ischaemia as the cause of the chest pain. Hence, angina 
pectoris is ultimately a clinical diagnosis.16'91 
If CAD that is unavailable for further revascularisation is demonstrated on coronary angiography, 
the patient can be considered to suffer from "verified" refractory angina pectoris. As mentioned 
above, there is a group of patients who are unable to undergo coronary angiography in order to 
establish the diagnosis refractory angina pectoris. It would be of clinical benefit if patients with 
"probable" refractory angina pectoris (not verified by coronary angiography) could be diagnosed 
on clinical criteria only, in line with the guidelines for the management of stable angina pectoris 
issued by the ESC and the American College of Cardiology/American Heart Association. There 
is a need to acknowledge this patients group as the same additional symptomatic treatment 
modalities available for patients with "verified" refractory angina, might also be used for 
symptom relief in this patient group. 
Until recently, patients with refractory angina pectoris seem to have been disregarded, probably 
because of a lack of knowledge of additional treatment possibilities. The responsible physician 
often informs the patient that "nothing more can be done", which is very disheartening for the 
patient. This situation is most likely to have a negative impact on the patient's psychological well-
being. 
Several reports concerning additional treatment modalities have been presented in recent 
decades.63'12"'133'188'2"3'216 Thus, it is of great importance to identify patients with refractory angina 
pectoris and patients who might be suffering from refractory angina pectoris. The choice of 
treatment demands individual evaluation and is dependent on the patient's physical as well as 
mental condition. According to the report by the ESC joint study group on the treatment of 
refractory angina pectoris, neuromodulation techniques, TENS and SCS, were recommended as 
the treatment of choice in refractory angina pectoris.135 In addition, cardiac rehabilitation in terms 
of risk factor management, such as smoking cessation and weight reduction is important. 
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Furthermore, regular physical activity, as an element in the cardiac rehabilitation, may also 
improve anginal symptoms.83 
6.4 PROGNOSIS AND QUALITY OF LIFE IN PATIENTS WITH REFRACTORY ANGINA PECTORIS 
The prognosis in patients with refractory angina pectoris has so far not been described. In Paper 
II, patients with refractory angina pectoris were followed up for one year with regard to fatality 
rate and cause of death. Approximately 10% of the patients in the refractory angina pectoris 
group died during the follow-up period and the main cause of death was cardiac disease. 
Compared with other patients group with stable angina, the fatality rate is high.""'11" However, 
the fatality rate was comparable those of other populations of patients with refractory angina 
pectoris treated with SCS or patients with severe angina pectoris and increased surgical risk (the 
ESBY patients).65,200 
Both the refractory group and the revascularisation group suffered from severe angina pectoris at 
the time of the revascularisation conference. After one year of follow-up, the anginal functional 
class of the patients in the revascularisation group was markedly improved compared with the 
refractory patients. The improvement in the refractory angina pectoris group may reflect a 
spontaneous variation in anginal symptoms, and that patients are more likely to be referred for 
coronary angiography at a time when the symptoms are more pronounced. In addition, 29 of the 
patients in the refractory group received symptomatic treatment after the revascularisation 
conference. 
The angina symptoms seem to have a great impact on the patients' quality of life with regard to 
physical function and physical well-being (bodily pain, general health and somatic function) as 
these dimensions of quality of life were impaired in the refractory group compared with the 
revascularisation group after one year of follow-up. The relationship between anginal symptoms 
and quality of life has been demonstrated in, for example, the RITA trial; the more pronounced 
the angina pectoris, the greater the negative impact on quality of life.163 In the RITA trial 
symptom relief also appeared to be related to increased mobility as well as general well-being. 
Compared to a normative Swedish population using SF-36, the refractory patients have impaired 
quality of life in most of the dimensions, except social function and mental health, after one year 
of follow-up (Fig. 3). The revascularisation group, which obtained adequate symptom relief, 
presented quality of life scores comparable to those of the normative Swedish population after 
one year of follow-up. 
The dimensions assessing mental health, social and emotional function do not seem to be 
affected by the severity of the anginal pain in the refractory group. According to studies and 
clinical experience, this is in contrast with patients with other chronic pain syndromes, such as 
low back pain, fibromyalgia and whiplash disorders, where the patients' mental as well as physical 
health is seriously affected.28'32,133'142'147,163 For example, compared with fibromyalgia patients, the 
patients in the refractory angina pectoris group seem to have a better quality of life according to 
the SF-36, especially with regard to bodily pain, social functioning and mental health (Fig. 3).133,142 
43 
These results 
are in 
accordance with 
the clinical 
impression that 
patients with 
refractory 
angina pectoris 
seem to have 
better coping 
strategies 
compared with 
patients with 
long-term pain 
conditions. This 
is quitea 
contradiction, as 
it would be reasonable to assume that patients suffering from refractory angina pectoris would 
have poorer quality of life than patients with long-term pain conditions, as the refractory patients' 
pain - unlike long-term pain - might actually be lethal. A possible rationale for this may be that 
severe angina pectoris is well defined and more readily accepted by the physicians and by the 
society in general and thus considered a "high status" diagnosis. In contrast, other chronic pain 
conditions, such as fibromyalgia and low back pain, are less well defined and often lack objective 
physical findings. These conditions have considerably "lower status". 
As shown in the revascularisation group and in previous studies, symptom relief is of the 
outmost importance for the quality of life in patients with refractory angina pectoris.73,165 As 
mentioned above, neuromodulation techniques, such as TENS or SCS, are the treatment of 
choice in patients with refractory angina pectoris.135 The results from the ESBY study indicate 
that SCS is effective, with regard to symptom relief and improvement in quality of life, in a group 
of patients with severe angina pectoris, no prognostic benefit from CABG and with an increased 
surgical risk.73'140 Thus, patients with "verified" as well as "probable" refractory angina pectoris 
should be considered for additional treatment modalities aiming at symptom relief and 
improvement in quality of life. 
6.5 WHEN IS REVASCULARISATION APPROPRIATE FOR SYMPTOMATIC RELIEF IN PATIENTS 
WITH STABLE ANGINA PECTORIS? 
According to the results form the ESBY study patients with increased surgical risk undergoing 
CABG and SCS, have long-lasting symptom relieving effect of the treatment as well as long-
lasting improvement in their quality of life.73'140 The risk of developing complications in 
connection with revascularisation procedures is not negligible. 16'42-143-173 Re do CABG has an 
estimated mortality rate of 5-21%.16,151 
In the ESBY study (Paper III), a considerable number of the CABG patients (n=7) died in 
connection with the primary intervention and in nine of the eleven patients with focal cerebral 
ischaemia in the CABG group, the event was related to the surgery (in to tal 17.6% of the CABG 
patients). Furthermore, 27.5% of the CABG patients developed neuropsychological deficit after 
the intervention in terms of astheno-emotional disorder (AED). The patients in the ESBY study, 
undergoing CABG had a higher cerebrovascular morbidity in terms of stroke and TIA than what 
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FIGURE 3. Quality of life according to the SF-36 in the REFRACT group and the REVASC group one year after 
the revascularisation conference, compared with a normative Swedish population and a group of patients with 
fibromyalgia.23 Higher values indicate better quality of life. 
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has been reported for patients in other studies.42'143'1'3'"1,202 However, the frequency of 
neuropsychological complications in the CABG group was comparable to that reported in other 
studies.1"'19"'194 These patients were considered patients high-risk patients in terms of 
complications in connection with surgery. Thus, a high morbidity of focal cerebral ischaemia was 
expected. 
In patients without increased surgical risk, in the revascularisation group (Paper II), six patients 
(4.3%) developed stroke and nine patients (6.5%) suffered serious perioperative and 
postoperative cardiac complications in the revascularisation group. Hence, neurological 
complications in association with revascularisation procedures are not negligible in patients 
without a previously known increased surgical risk. Patients who underwent SCS (Paper III) or 
additional symptomatic treatment (Paper II), did not develop any cerebral complications in 
connection with the interventions. 
In Paper III, the results indicate that preoperative presence of small artery disease in the brain, i.e. 
white matter disease (diagnosed by cerebral MRI), might be a predictor of development of 
neurological (i.e. focal cerebral ischaemia) and neuropsychological complications (i.e. AED) after 
CABG. However, patients with WMD undergoing SCS did not have an increased risk of 
developing neurological or neuropsychological complications compared with the CABG group. 
Thus, in order to assess the risk of cerebral injury, a preoperative cerebral MRI might be of value 
in patients with increased surgical risk. 
A question that was not addressed in Paper III was whether the patients with and without WMD 
diseases differed with regard to risk factors for developing neurological and neuropsychological 
complications. There were no differences between the patients with and without WMD with 
regard to age, gender distribution, presence of clinically significant carotid stenosis, previous 
CABG or previous AED, but the groups differed with regard to pre-existing cerebrovascular 
disease (i.e. focal cerebral ischaemia) (p<0.01). It is reasonable to assume that patients with 
previous focal cerebral ischaemia have a more generalised atherosclerotic disease. Hence, these 
patients may also have an increased risk of developing WMD, as it is a manifestation of 
atherosclerosis in the small arteries in the brain. However, there were no differences between the 
SCS and the CABG groups with regard to pre-existing cerebrovascular disease. Thus, the patients 
with WMD in both the CABG and the SCS groups could be considered to be equally at risk of 
developing cerebral complications. Nevertheless, more patients with WMD undergoing CABG 
developed neurological as well as neuropsychological complications compared with the SCS 
group. 
When assessing whether a patient is suitable for undergoing a revascularisation procedure or not, 
technical feasibility, indication for surgery as well as the risk of developing cerebral complications 
and the risk of death, should be taken into account. The increased mortality rate in connection 
with repeat revascularisation in patients who have previously undergone CABG should be 
considered, as mentioned above.16'151 
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TABLE 4. Risk factors for developing focal cerebral ischemia and AED in the patients with and 
without WMD before intervention. 
WMD (n=71) No WMD (n=25) P value 
Age (mean) 69 66 0.24 
Gender; female/male (n) 14/57 (20/80%) 4/21 (16/84%) 0.68 
Carotid artery stenosis >70% (n) 14 (20%) 4(16%) 0.72 
Previous CABG (n) 15(21%) 8 (32%) 0.27 
Pre-existing AED (n) 21 (30%) 4 (16%) 0.18 
Pre-existing 19(27%) 0 <0.01 
cerebrovascular disease (n) 
AED indicates Astheno-Emotional Disorder; CABG, Coronary Artery Bypass Grafting; WMD, White Matter 
Disease. 
Considering the high risk of complications in connection with revascularisation procedures, 
patients suffering from mild or moderate stable angina pectoris (CCS class 1-2) should not be 
endangered by undergoing revascularisation procedures for symptomatic relief only. In these 
patients, symptomatic relief can usually be obtained by optimising the medication.120 In contrast, 
patients with severe angina pectoris (CCS class 3-4) might benefit from revascularisation 
procedures for symptomatic relief. However, if the indication for revascularisation is stricdy 
symptomatic, patients with a high risk of developing complications in connection with the 
procedure need to be identified. In these patients the potential benefit of symptom relief does 
not correspond to the risk of developing complications. In Paper III, it was suggested that 
preoperative cerebral WMD may be a predictor for the development of cerebral complications, in 
addition to other known risk factors for cerebrovascular lesions. Hence, preoperative cerebral 
MRI may be a tool for identifying patients with increased of cerebral complications in connection 
with surgery. If investigations indicate that the patient have a too high risk of complications in 
connection with a revascularisation procedure, additional symptomatic treatments should be 
considered as an option. 
In patients with severe angina pectoris who are considered inappropriate for further 
revascularisation (patients with refractory angina pectoris) and in patients with increased surgical 
risk of developing cerebral complications, additional symptomatic treatment modalities, such as 
neuromodulation techniques (TENS and SCS) may be a therapeutic alternative.135,140 These 
treatment modalities are effective for symptomatic relief of angina pectoris and as the SCS 
implantation is only a minor surgical procedure, unconnected with development of cerebral 
complications, SCS is suitable for somatically diseased patients with increased risk surgical risk. 
Figure 4 suggests a flow-chart for the management of patients with severe angina pectoris. 
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Patients with stable angina pectoris (CCS class 3 or 4) 
with clinically established reversible myocardial ischaemia 
and optimised pharmacological treatment 
No Yes 
Yes No 
No Yes 
Yes No 
Yes No 
Revascularisation 
Revascularisation 
Revascularisation 
CAD in coronary angiography? 
Presence of white matter disease 
on cerebral MRI? 
Refractory angina pectoris 
Investigation for further 
treatment with TENS/SCS 
Prognostic benefit of 
revascularisation? 
Revascularisation feasible? 
Revascularisation not appropriate 
Investigation for further treatment 
with TENS/SCS 
Increased risk of cerebral 
complications in connection 
to revascularisation? 
Further investigation 
Syndrome X? 
Prinzmetal angina? 
Chest pain of 
non-cardiac origin? 
FIGURE 4. A suggestion of a flow-chart for the management of patients with severe angina pectoris. 
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6.6 SAFETY OF SPINAL CORD STIMULATION IN ANGINA PECTORIS 
There have been previous reports regarding the long-term effects and safety of SCS.63,96,176,183,206 
However, most of these studies have drawbacks in terms of being too small, retrospective and/or 
non-randomised. Further long-term studies regarding the safety of SCS treatment were therefore 
needed. Despite previous results from the ESBY study, the long-term mortality of SCS in 
comparison with CABG has previously not been described. Hence, the aim of the study 
presented in Paper IV was to assess the long-term effects and safety of SCS treatment compared 
with CABG treatment. 
CABG is associated with a certain mortality risk in connection with the intervention, whereas 
implantation of the SCS device is a minor surgical procedure. This was reflected in the higher 
mortality rate in the CABG group after six months of follow-up.140 According to previous results 
from the ESBY study, and the results presented in Paper IV, the SCS group and the CABG 
group had comparable mortality after two years of follow-up and after five years of follow-up. 
On these two follow-up occasions, the total mortality rate of the ESBY patients was 10.7% and 
27.9 %.73 This is a higher mortality rate than that described in other studies of patients with 
pharmacologically treated angina pectoris.7,78'213 However, when compared with a Swedish angina 
population with similar extent of CAD and pharmacological treatment, the mortality rate (4.3% 
at 12 months and 9.1% at 21 months) was comparable with that of the ESBY study patients.40 As 
mentioned above, the high mortality rate was not unexpected, as these patients were considered 
to have an increased surgical risk due to generalised atherosclerosis and concomitant diseases. In 
addition, there were no differences between the groups with regard to the number of deaths due 
to cardiac or cerebrovascular disease after two years of follow-up. Furthermore, when compared 
to patients with risk factors for CABG randomised to PCI or CABG, the three-year survival in 
both these groups was comparable to that of the ESBY study patients.73'130 
Data from the ESBY study indicate that SCS is as safe as CABG in the long-term perspective, 
with regard to mortality and causes of death. However, CABG seems to be associated with an 
increased mortality in the short-term perspective. 
The long-term safety of the SCS treatment was also evaluated in terms of complications in 
connection with the treatment (Paper IV). The most feared complication of SCS is intraspinal 
infection and subsequent serious neurological sequelae. There were no cases of intra spinal 
infection in the ESBY study. In addition, there has been no case of intraspinal infection in 
Göteborg in any of the over 800 patients implanted since 1985, when SCS for angina pectoris 
was introduced. One patient, out of the 57 patients who were implanted with a SCS device during 
the two-year follow-up period, developed a postoperative subcutaneous infection in the pulse 
generator skin pocket. As the SCS system is fully implanted, without percutaneous connections, 
the risk of late occurring infections is small. Other centres report a similar frequency of 
complications in connection with SCS treatment for angina.2"'96,176 
6.7 LONG-TERM EFFECTS OF SPINAL CORD STIMULATION IN ANGINA PECTORIS 
After two years of follow-up, more than 80% of the patients implanted with a SCS device 
experienced symptomatic improvement in terms of reduced frequency and severity of angina 
attacks. The success rate of the SCS treatment in the ESBY patients is comparable to results from 
other studies.65,Hence, SCS seems to be an effective treatment modality also in the long-term 
perspective, which may also be reflected by the long-lasting improvement in quality of life. ' 3 
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Several studies have demonstrated that SCS reducess hospitalisation due to cardiac disease after 
implantation and that SCS in refractory angina pectoris is more cost-effective than 
pharmacological treatment in terms of the number of hospital days and/or hospital admissions. 
31,148,153,217 According to a study by Yu et al., the cost of SCS was balanced after 16 months, 
including costs of hospitalisation, additional investigations and device related costs. However, 
SCS has not previously been compared with invasive procedures for symptomatic treatment of 
severe angina pectoris. 
According to Paper IV, the hospitalisation rate in the SCS group and CABG group was similar. 
The CABG group had more hospital days due to cardiac events, but there were no differences 
between the groups with regard to the number of cardiac events. However, the CABG group 
needed twice as many days of hospital care in connection with the primary intervention as the 
SCS group (11 days compared to 5 days). At present, the average length of stay in hospital in 
connection with SCS implantation is approximately 2.5 days, compared with 9 days for CABG 
surgery. Hence, the long-term morbidity is comparable in SCS- treated patients and in patients 
with increased surgical risk surgical risk u ndergoing CABG. 
In addition, SCS was shown to be less expensive than CABG, not only with regard to the primary 
intervention cots, but also with regard to the total cost during the two-year follow-up period. 
Previous studies have shown that the total health-service costs over five years are similar for 
patients undergoing CABG and patients undergoing PCI.105 However, there are no studies 
comparing the health costs of PCI and SCS. However, "the cost of impaired quality of life" or 
"the cost of suffering" caused by a stroke or AED is not measurable. According to Paper III, by 
undergoing a preoperative MRI and assessing the presence of WMD, the risk of cerebral 
complications may be predicted before undergoing CABG is carred out on high-risk patients. 
Thus, theoretically, the relatively low cost of a cerebral MRI may prevent suffering for the patient 
as well as increased health care costs for society. 
Thus, since the cost of symptom relief appears to be similar for revascularisation procedures and 
SCS in patients with severe angina pectoris, it is of great importance to evaluate carefully which 
method of symptom relief might be the most beneficial for the patient, in terms of technical 
feasibility, risk of cerebral complications and death. Symptom relief seems to be crucial for the 
quality of life of patients with severe angina pectoris and can successfully be obtained either by 
conventional revascularisation procedures or with SCS. 
49 
CONCLUSIONS 
A significant number of patients seem to suffer from refractory angina pectoris. This patient 
group has advanced cardiac disease as well coronary artery disease. Even though the majority 
of patients have coronary artery disease, some patients need further evaluation to confirm 
current myocardial ischaemia. Furthermore, there are probably a number of patients who 
would benefit from optimised medication. The refractory patients appear to suffer from 
severe cardiac disease as well as severe coronary artery disase. 
The main reason why the refractory patients are considered inappropriate for further 
revascularisation is unsuitable coronary anatomy. In patients with prior CABG, the main 
contributing factor is a potential risk of damaging pre-existing grafts and in patients who not 
have undergone any previous CABG, extracardiac disease is the main contributing factor for 
rejection. 
Patients with refractory angina pectoris have a high fatality rate and impaired quality of life. 
In contrast, cerebrovascular morbidity seems not to be pronounced. The anginal pain seems 
to limit their physical activity and impair their physical well-being, while social function, 
emotional function and mental health seem to be unaffected. This is in contrast with patients 
with chronic pain syndromes, whose quality of life is severely impaired physically as well as 
mentally and socially. This observation is in accordance with the clinical impression, that 
patients with refractory angina pectoris seem to have better cooping strategies compared with 
patients with long-term pain conditions. 
Preoperative presence of white matter disease, identified by cerebral MRI, seems to be a 
predictor of cerebral complications after CABG. Hence, preoperative cerebral MRI might be 
used as a screening tool in patients with increased surgical risk and no prognostic benefit 
from CABG, in order to choose the most appropriate symptomatic treatment modality. 
SCS, one of the treatments of choice in refractory angina pectoris, is concluded to be a safe 
treatment modality in terms of cerebral complications in connection with the implantation, 
long-term morbidity, mortality and frequency of treatment complications. 
Long-term treatment with SCS is concluded to be effective in terms of symptom relief. In 
addition, SCS is concluded to be less expensive than CABG in patients with increased 
surgical risk and no prognostic benefit from surgery. 
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8. CLINICAL IMPLICATIONS AND FUTURE PERSPECTIVES 
This thesis demonstrates that there seems to be a considerable number of patients who suffer 
from refractory angina pectoris and that there is a need to acknowledge this patient group. Before 
confirming the diagnosis the application of symptomatic treatment, an attempt should be made 
to optimise the medication and myocardial ischaemia should be confirmed. It is of the outmost 
importance that this patient group is identified and subsequently treated with additional 
symptom-relieving treatment modalities, irrespective of whether the patient suffers from 
"verified" or "probable" refractory angina pectoris. Refractory angina pectoris is an important 
issue for cardiologists as well as for specialists in pain medicine, as many of the available 
treatment modalities for symptomatic relief are frequently used in pain medicine. 
Furthermore, the guidelines concerning refractory angina pectoris need to be regularly updated, 
as reports regarding research on additional treatment modalities providing new information on 
the efficiency, safety and side effects of these methods, are constantly published. In addition, 
further studies regarding the long-term prognosis of patients with refractory angina pectoris, as 
well as randomised treatment studies are needed in order to improve the understanding and 
treatment of this condition. 
Even when matched for age and gender, the refractory patients had more severe coronary artery 
disease than patients accepted for revascularisation. Studies regarding the genetical characteristics 
of this patient groups would be of value in order to investigate whether patients with refractory 
angina pectoris might have a genetic predisposition for coronary artery disease. 
In patients with severe angina pectoris, symptom relief seems to be of great importance with 
regard to quality of life. In patients with refractory angina pectoris, the quality of life seems to be 
impaired with regard to physical function and physical well-being, but not with regard to mental 
health and social function. This is in contrast with patients suffering from chronic pain 
conditions, whose quality of life is impaired with regard both to physical function as well as 
mental health. Thus, patients with refractory angina pectoris seem to have better coping strategies 
for managing their pain. Studies to further characterise and compare these patients groups would 
be of value. 
Spinal cord stimulation can be considered to be a safe and effective therapeutic option for 
patients with refractory angina pectoris as well as patients with severe angina pectoris and 
increased surgical risk. However, approximately 20% of patients treated with neuromodulation 
do not receive adequate symptom relief. Thus, further treatment strategies for patients with 
refractory angina pectoris are needed. 
When assessing the risk of cerebral complications, it can be concluded that the presence of white 
matter disease on cerebral magnetic resonance imaging may be a predictor of a risk of cerebral 
injury after CABG. 
This thesis underlines the importance of carefully evaluatating which therapeutic symptom-
relieving method may be the most beneficial for patients with severe angina pectoris who do not 
have a prognostic benefit from revascularisation. 
Finally, further studies are needed in order to fully elucidate the mechanisms of SCS in angina 
pectoris. 
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